1
|
Masson W, Barbagelata L, Lobo M, Berg G, Lavalle-Cobo A, Nogueira JP. Association between maternal epicardial adipose tissue, gestational diabetes mellitus, and pregnancy-related hypertensive disorders: a systematic review and meta-analysis. Arch Gynecol Obstet 2023; 308:1057-1066. [PMID: 36695898 DOI: 10.1007/s00404-023-06933-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 01/12/2023] [Indexed: 01/26/2023]
Abstract
Several small studies have evaluated the association between epicardial adipose tissue (EAT) and pregnancy-related cardiovascular risk factors such as gestational diabetes mellitus (GDM) or hypertensive disorders. The objective of this study was to quantitatively compare EAT thickening between patients with GDM or pregnancy-related hypertensive disorders and healthy controls. This systematic review and meta-analysis were performed according to PRISMA guidelines. A literature search was performed to detect studies that have quantified EAT in women with GDM and pregnancy-related hypertensive disorders compared to a control group. The primary outcome was EAT thickening estimated by ultrasound expressed in millimeters. Random or fixed effects models were used. Nine observational studies including 3146 patients were identified and considered eligible for this systematic review. The quantitative analysis showed that patients with GDM have a higher EAT thickness (mean difference: 1.1 mm [95% confidence interval: 1.0-1.2]; I2 = 24%) compared to the control group. Moreover, patients with pregnancy-related hypertensive disorders showed higher EAT thickness (mean difference: 1.0 mm [95% confidence interval: 0.6-1.4]; I2 = 83%) compared to the control group. In conclusion, this study demonstrated that EAT thickening is increased in patients with GDM and pregnancy-related hypertensive disorders compared with healthy controls. Whether or not this association is causal should be evaluated in prospective studies.
Collapse
Affiliation(s)
- Walter Masson
- Cardiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
| | - Leandro Barbagelata
- Cardiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Martín Lobo
- Cardiology Department, Hospital Militar Campo de Mayo, Buenos Aires, Argentina
| | - Gabriela Berg
- Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Laboratorio de Lípidos y Aterosclerosis, Universidad de Buenos Aires, Buenos Aires, Argentina
- CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | | | - Juan P Nogueira
- Centro de Investigación en Endocrinología, Nutrición y Metabolismo (CIENM), Facultad de Ciencias de la Salud, Universidad Nacional de Formosa, Formosa, Argentina
| |
Collapse
|
2
|
Azevedo-Garcia LG, Torres-Leal FL, Aristizabal JC, Berg G, Carvalho HB, De Moraes ACF. Reliability and Validity Estimate of the Pro-Inflammatory/Anti-Inflammatory Food Intake Score in South American Pediatric Population: SAYCARE Study. Int J Environ Res Public Health 2023; 20:1038. [PMID: 36673794 PMCID: PMC9859242 DOI: 10.3390/ijerph20021038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 12/19/2022] [Accepted: 01/03/2023] [Indexed: 06/17/2023]
Abstract
Chronic low-grade inflammation may be associated with the development of chronic non-communicable diseases in young populations, often lasting to adulthood. Studies show that the diet is related to chronic inflammation. The Pro-inflammatory/Anti-inflammatory Food Intake Score (PAIFIS) is an indicator that measures the inflammatory potential of the diet, with the help of validated tools that assess food consumption. The validation of tools that assess inflammatory dietary patterns in young populations to produce valid and reliable results is essential to guide disease prevention strategies for adulthood. METHODS This study aimed to estimate the Pro-inflammatory/Anti-inflammatory Food Intake Score (PAIFIS) in children and adolescents in South America and to test its reliability and validity using a food frequency questionnaire (FFQ) and an inflammatory biomarker. This work consists of a validation study in a sample of children and adolescents conducted in South America (SAYCARE Study). The habitual consumption of food contributing to calculating the PAIFIS was obtained through an FFQ and 24 h Dietary Recall (24HDR). Reliability was tested using the FFQ (FFQ1 × FFQ2), using Spearman's correlation coefficient to estimate the agreement between measurements. The validity of the PAIFIS was tested using 24HDR and the inflammatory biomarker C-reactive protein (CRP) using Spearman's correlation and multilevel linear regression. RESULTS For children and adolescents, pro- and anti-inflammatory food groups showed Spearman's correlation coefficients ranging from 0.31 to 0.66, convergent validity ranging from 0.09 to 0.40, and criterion validity for a reliability range from -0.03 to 0.18. The PAIFIS showed Spearman's correlation coefficients for reliability ranging from 0.61 to 0.69, convergent validity from 0.16 to 0.23, and criterion validity from -0.03 to 0.24. CONCLUSION The PAIFIS showed acceptable reliability, weak convergent validity, and weak criterion validity in children and adolescents.
Collapse
Affiliation(s)
- Lívia Gabriele Azevedo-Garcia
- YCARE (Youth/Child and Cardiovascular Risk and Environmental) Research Group, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 01246-903, Brazil
| | - Francisco Leonardo Torres-Leal
- Metabolic Diseases, Exercise and Nutrition (DOMEN) Research Group, Federal University of Piauí, Teresina 64049-550, Brazil
| | - Juan Carlos Aristizabal
- Grupo de Investigación en Fisiología y Bioquímica (PHYSIS), Universidad de Antioquia, Medellín 050010, Colombia
| | - Gabriela Berg
- Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956, Buenos Aires C1113AAD, Argentina
- Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires C1120AAF, Argentina
- Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina
| | - Heráclito B. Carvalho
- YCARE (Youth/Child and Cardiovascular Risk and Environmental) Research Group, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 01246-903, Brazil
| | - Augusto César Ferreira De Moraes
- The University of Texas Health Science Center at Houston, School of Public Health Austin Campus, Michael & Susan Dell Center for Healthy Living, Austin, TX 78701, USA
- Graduate Program in Public Health, Graduate Program in Epidemiology, School of Public Health, University of Sao Paulo, Sao Paulo 01246-904, Brazil
| |
Collapse
|
3
|
Carro N, Ibar C, D'Adamo P, Gonzalez D, Berg G, Fabre B, Lozada M. Hair cortisol reduction and social integration enhancement after a mindfulness-based intervention in children. Child Care Health Dev 2023; 49:73-79. [PMID: 35312189 DOI: 10.1111/cch.13008] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 03/14/2022] [Accepted: 03/16/2022] [Indexed: 12/16/2022]
Abstract
BACKGROUND Over recent decades, chronic stress at an early age has become a worrying health problem in children. We seek to evaluate an intervention involving mindfulness-based practices and prosocial activities in 7- to 8-year-old children. METHODS Stress levels were determined using hair cortisol concentration (HCC), and social integration was measured by means of a sociogram. The program had previously proven to be effective in decreasing salivary cortisol levels and in favouring social integration in children. A total of 35 children participated in the study: 18 constituted the intervention group and 17 the wait-list group. In both groups, HCC and social integration were evaluated before and after the intervention conducted throughout an entire school year. RESULTS The experimental group showed a significant reduction in HCC, as well as significant enhancement of social integration levels, whereas no changes were observed in the wait-list group. CONCLUSIONS This is the first research to show that HCC, a reliable neuroendocrine indicator, decreased as a result of a mindfulness-based program. This successful outcome adds new evidence to previous findings regarding the reduction of chronic stress in children following participation in this program.
Collapse
Affiliation(s)
- Natalia Carro
- INIBIOMA-CONICET, National University of Comahue, Neuquén, Argentina
| | - Carolina Ibar
- Faculty of Pharmacy and Biochemistry, Clinical Biochemistry Department, University of Buenos Aires, Buenos Aires, Argentina
| | - Paola D'Adamo
- CyC IPEHCS-CONICET, National University of Comahue, Neuquén, Argentina
| | - Diego Gonzalez
- Faculty of Pharmacy and Biochemistry, Clinical Biochemistry Department, University of Buenos Aires, Buenos Aires, Argentina
| | - Gabriela Berg
- Faculty of Pharmacy and Biochemistry, Clinical Biochemistry Department, CONICET, University of Buenos Aires, Buenos Aires, Argentina
| | - Bibiana Fabre
- Faculty of Pharmacy and Biochemistry, INFIBIOC, Clinical Biochemistry Department, University of Buenos Aires, Buenos Aires, Argentina
| | - Mariana Lozada
- INIBIOMA-CONICET, National University of Comahue, Neuquén, Argentina
| |
Collapse
|
4
|
Fabre B, Fernandez Machulsky N, Olano C, Jacobsen D, Gómez ME, Perazzi B, Zago V, Zopatti D, Ferrero A, Schreier L, Berg G. Remnant cholesterol levels are associated with severity and death in COVID-19 patients. Sci Rep 2022; 12:17584. [PMID: 36266451 PMCID: PMC9584251 DOI: 10.1038/s41598-022-21177-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2022] [Accepted: 09/23/2022] [Indexed: 01/13/2023] Open
Abstract
Coronavirus disease-19 (COVID-19) patients with severe complications present comorbidities like cardiovascular-disease, hypertension and type-2 diabetes mellitus (DM), sharing metabolic alterations like insulin resistance (IR) and dyslipidemia. Our objective was to evaluate the association among different components of the lipid-lipoprotein profile, such as remnant lipoprotein (RLP)-cholesterol, in patients with COVID-19, and to analyze their associations with the severity of the disease and death. We studied 193 patients (68 (29-96) years; 49.7% male) hospitalized for COVID-19 and 200 controls (46 (18-79) years; 52.5% male). Lipoprotein profile, glucose and procalcitonin were assessed. Patients presented higher glucose, TG, TG/HDL-cholesterol and RLP-cholesterol levels, but lower total, LDL, HDL and no-HDL-cholesterol levels (p < 0.001). When a binary logistic regression was performed, age, non-HDL-cholesterol, and RLP-cholesterol were associated with death (p = 0.005). As the COVID-19 condition worsened, according to procalcitonin tertiles, a decrease in all the cholesterol fractions (p < 0.03) was observed with no differences in TG, while levels of RLP-cholesterol and TG/HDL-cholesterol increased (p < 0.001). Lower levels of all the cholesterol fractions were related with the presence and severity of COVID-19, except for RLP-cholesterol levels and TG/HDL-cholesterol index. These alterations indicate a lipid metabolic disorder, characteristic of IR states in COVID-19 patients. RLP-cholesterol levels predicted severity and death in these patients.
Collapse
Affiliation(s)
- Bibiana Fabre
- grid.7345.50000 0001 0056 1981Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956 (C1113AAD), Buenos Aires, Argentina ,grid.7345.50000 0001 0056 1981Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Nahuel Fernandez Machulsky
- grid.7345.50000 0001 0056 1981Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956 (C1113AAD), Buenos Aires, Argentina ,grid.7345.50000 0001 0056 1981Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Carolina Olano
- grid.7345.50000 0001 0056 1981Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956 (C1113AAD), Buenos Aires, Argentina ,grid.7345.50000 0001 0056 1981Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Darío Jacobsen
- grid.7345.50000 0001 0056 1981Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956 (C1113AAD), Buenos Aires, Argentina
| | - María Eugenia Gómez
- grid.7345.50000 0001 0056 1981Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956 (C1113AAD), Buenos Aires, Argentina
| | - Beatriz Perazzi
- grid.7345.50000 0001 0056 1981Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956 (C1113AAD), Buenos Aires, Argentina ,grid.7345.50000 0001 0056 1981Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Valeria Zago
- grid.7345.50000 0001 0056 1981Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956 (C1113AAD), Buenos Aires, Argentina ,grid.7345.50000 0001 0056 1981Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina ,grid.7345.50000 0001 0056 1981Facultad de Farmacia y Bioquímica, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Damián Zopatti
- grid.7345.50000 0001 0056 1981Facultad de Medicina, Dirección de Estadística y Archivo Médico, Hospital de Clínicas José de San Martin, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Andrés Ferrero
- grid.7345.50000 0001 0056 1981Facultad de Medicina, Director Adjunto Hospital de Clínicas José de San Martin, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Laura Schreier
- grid.7345.50000 0001 0056 1981Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956 (C1113AAD), Buenos Aires, Argentina ,grid.7345.50000 0001 0056 1981Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Gabriela Berg
- grid.7345.50000 0001 0056 1981Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Bioquímica Clínica I, Junín 956 (C1113AAD), Buenos Aires, Argentina ,grid.7345.50000 0001 0056 1981Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina ,grid.7345.50000 0001 0056 1981Facultad de Farmacia y Bioquímica, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
5
|
Berg G, Barchuk M, Ancel P, Svilar L, Miksztowicz V, Yñon D, Nogueira J, Rubio M, Schreier L, Dutour A, Martin J, Gaborit B. Bioactive lipids and lipoprotein lipase in epicardial adipose tissue from patients with coronary artery disease: Unfolding a missing link. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
6
|
Berg G, Barchuk M, Lobo M, Nogueira JP. Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis. Diabetes Metab Syndr 2022; 16:102562. [PMID: 35816950 DOI: 10.1016/j.dsx.2022.102562] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 06/25/2022] [Accepted: 06/28/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND AIMS Glucagon-like peptide-1 (GLP-1) analogues reduce body fat and cardiovascular events in patients with type 2 diabetes. Accumulation of epicardial adipose tissue (EAT) is associated with increased cardio-metabolic risks and coronary events in type 2 diabetes. METHODS A systematic review and meta-analysis were performed from Glucagon-like peptide-1 analogues therapy on type 2 diabetes patients, reporting data from changes in EAT, after searching the PubMed/MEDLINE, Embase, Science Direct, Scopus, Google Scholar, and Cochrane databases. RESULTS It has been found a limited number of studies, a total of 4 studies (n = 160 patients with GLP-1 analogues therapy) were included in the final analysis. Pooled analysis revealed that GLP-1 analogues reduce EAT (MD: 1.83 mm [-2.50; -1.10]; P < 0.01). Compared with the patients before the treatment, the patients after the treatment had a smaller HbA1c (MD -1.10%[-1.80; -0.30]; p = 0.0143) and body mass index was reduced (MD -2.20 kg/m2[-3.70; -0.60]; p = 0.0058), GLP-1 therapy reduced low-density lipoprotein levels (MD-13.53 mg/dL [-21.74; -5.31]; p = 0.001) and reduced triglycerides levels significantly (MD -18.32 -28.20 mg/dL; -8.50); p = 0.0003). CONCLUSIONS This meta-analysis suggests that the amount of EAT is significantly reduced in T2D patients with Glucagon-like peptide-1 analogues.
Collapse
Affiliation(s)
- Gabriela Berg
- Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Laboratorio de Lípidos y Aterosclerosis, Universidad de Buenos Aires, Buenos Aires, Argentina; Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina; CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
| | - Magali Barchuk
- Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Laboratorio de Lípidos y Aterosclerosis, Universidad de Buenos Aires, Buenos Aires, Argentina; Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina; CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
| | - Martin Lobo
- Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology, Buenos Aires, Argentina; Cardiology Department, Hospital Militar Campo de Mayo, Buenos Aires, Argentina.
| | - Juan Patricio Nogueira
- Centro de Investigación en Endocrinología, Nutrición y Metabolismo (CIENM), Facultad de Ciencias de la Salud, Universidad Nacional de Formosa, Argentina.
| |
Collapse
|
7
|
Barchuk M, Ancel P, Miksztowicz V, Doukbi E, Svilar L, Yñón D, Nogueira JP, Rubio M, Schreier L, Dutour A, Martin JC, Gaborit B, Berg G. Epicardial Adipose Tissue Ceramides Are Related to Lipoprotein Lipase Activity in Coronary Artery Disease: Unfolding a Missing Link. Arterioscler Thromb Vasc Biol 2022; 42:e242-e251. [PMID: 35708030 DOI: 10.1161/atvbaha.122.317840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Epicardial adipose tissue (EAT) contributes to coronary artery disease (CAD). EAT presents a specific lipidomic signature, showing increased ceramides and other proinflammatory lipids content. Besides, LPL (lipoprotein lipase) activity in EAT would contribute to its expansion, supplying fatty acids to the tissue. Our aim was to evaluate the relations between LPL activity, regulators of LPL, and ceramides in EAT from CAD patients. METHODS We studied patients undergoing coronary bypass graft (CAD, n=25) and patients without CAD (no CAD, n=14). EAT and subcutaneous AT (SAT) were obtained, tissue LPL activity and its regulator's expression (ANGPTL4, GPIHBP1 [glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1], and PPARγ [peroxisomal proliferator-activated receptor γ]) were assessed. Tissue lipidomes were evaluated by UHPLC-MS, in positive and negative ionization modes. RESULTS LPL activity was higher in EAT from CAD (P<0.001), and in EAT than SAT in both groups (P<0.001). ANGPTL4 levels were lower, GPIHBP1 and PPARγ levels were higher in EAT from CAD (P<0.001). In both groups, EAT exhibited more ceramide (P=0.01), directly associated with LPL activity, being the strongest association with Cer18:1/24:1 (P<0.001). EAT Cer18:1/16:0 to Cer18:1/24:0 and Cer18:1/24:1 to 18:1/24:0 ratios were higher in CAD (P=0.03; P<0.001, respectively), the latter directly associated with LPL activity (r=0.63, P<0.001) GPIHBP1 levels (r=0.68, P<0.001), and inversely to EAT ANGPTL4 expression (r=-0.49, P=0.03). Pairwise partial correlation network showed associations among bioactive lipids and LPL and its regulators (P<0.001 in all cases). CONCLUSIONS The association between LPL activity, total ceramide, and the atherogenic ceramide ratios highlights the importance of the enzyme and these bioactive lipids contributing to the different metabolic profile of EAT in CAD.
Collapse
Affiliation(s)
- Magalí Barchuk
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina (M.B., L.S., G.B.)
- Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Argentina (M.B., V.M., G.B.)
| | - Patricia Ancel
- Aix-Marseille University, INSERM, INRAE, C2VN, France (P.A., E.D., L.S., A.D., J.C.M., B.G.)
| | - Verónica Miksztowicz
- Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Argentina (M.B., V.M., G.B.)
| | - Elisa Doukbi
- Aix-Marseille University, INSERM, INRAE, C2VN, France (P.A., E.D., L.S., A.D., J.C.M., B.G.)
| | - Ljubica Svilar
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina (M.B., L.S., G.B.)
- Aix-Marseille University, INSERM, INRAE, C2VN, France (P.A., E.D., L.S., A.D., J.C.M., B.G.)
| | - Daniel Yñón
- Universidad de Buenos Aires, Hospital de Clínicas "José de San Martín", División de Cirugía Cardiovascular, Argentina (D.Y., M.R.)
| | - Juan Patricio Nogueira
- Servicio de Docencia e Investigación, Hospital Central de Formosa, Facultad de Ciencias de la Salud, Universidad Nacional de Formosa, Argentina (J.P.N.)
| | - Miguel Rubio
- Universidad de Buenos Aires, Hospital de Clínicas "José de San Martín", División de Cirugía Cardiovascular, Argentina (D.Y., M.R.)
| | - Laura Schreier
- CRIBIOM, Criblage Biologique Marseille, Faculté de Medecine de la Timone, France (L.S.)
| | - Anne Dutour
- Aix-Marseille University, INSERM, INRAE, C2VN, France (P.A., E.D., L.S., A.D., J.C.M., B.G.)
- Endocrinology, Metabolic Diseases and Nutrition Department, Assistance Publique Hôpitaux de Marseille, France (A.D., B.G.)
| | - Jean Charles Martin
- Aix-Marseille University, INSERM, INRAE, C2VN, France (P.A., E.D., L.S., A.D., J.C.M., B.G.)
| | - Bénédicte Gaborit
- Aix-Marseille University, INSERM, INRAE, C2VN, France (P.A., E.D., L.S., A.D., J.C.M., B.G.)
- Endocrinology, Metabolic Diseases and Nutrition Department, Assistance Publique Hôpitaux de Marseille, France (A.D., B.G.)
| | - Gabriela Berg
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina (M.B., L.S., G.B.)
- Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Argentina (M.B., V.M., G.B.)
| |
Collapse
|
8
|
Finocchietto P, Perez H, Blanco G, Miksztowicz V, Marotte C, Morales C, Peralta J, Berg G, Poderoso C, Poderoso JJ, Carreras MC. Inhibition of Mitochondrial Fission by Drp-1 Blockade by Short-Term Leptin and Mdivi-1 Treatment Improves White Adipose Tissue Abnormalities in Obesity and Diabetes. Pharmacol Res 2021; 178:106028. [PMID: 34896541 DOI: 10.1016/j.phrs.2021.106028] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 11/25/2021] [Accepted: 12/06/2021] [Indexed: 01/11/2023]
Abstract
BACKGROUND Obesity and type 2 diabetes are chronic diseases characterized by insulin resistance, mitochondrial dysfunction and morphological abnormalities. OBJECTIVE We have investigated if dysregulation of mitochondrial dynamics and biogenesis is involved in an animal model of obesity and diabetes. METHODS The effect of short-term leptin and mdivi-1 -a selective inhibitor of Drp-1 fission-protein- treatment on mitochondrial dynamics and biogenesis was evaluated in epididymal white adipose tissue (WAT) from male ob/ob mice. RESULTS An increase in Drp-1 protein levels and a decrease in Mfn2 and OPA-1 protein expression were observed with enhanced and sustained mitochondrial fragmentation in ob/ob mice compared to wt C57BL/6 animals (p<0.05). The content of mitochondrial DNA and PGC-1α mRNA expression -both parameters of mitochondrial biogenesis- were reduced in ob/ob mice (p<0.05). Treatment with leptin and mdivi-1 significantly increased mitochondrial biogenesis, improved fusion-to-fission balance and attenuated mitochondrial dysfunction, thus inducing white-to-beige adipocyte transdifferentiation. Measurements of glucose and lipid oxidation in adipocytes revealed that both leptin and mdivi-1 increase substrates oxidation while in vivo determination of blood glucose concentration showed decreased levels by 50% in ob/ob mice, almost to the wt level. CONCLUSIONS Pharmacological targeting of Drp-1 fission protein may be a potential novel therapeutic tool for obesity and type 2 diabetes.
Collapse
Affiliation(s)
- P Finocchietto
- Laboratorio de Metabolismo del Oxígeno INIGEM-UBA-CONICET, Buenos Aires, Argentina; Departamento de Medicina, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
| | - H Perez
- Laboratorio de Metabolismo del Oxígeno INIGEM-UBA-CONICET, Buenos Aires, Argentina
| | - G Blanco
- Laboratorio de Inmunotoxicología (LaITo), IDEHU-CONICET, Universidad de Buenos Aires, Argentina
| | - V Miksztowicz
- Facultad de Medicina, Pontificia Universidad Católica Argentina (UCA), Instituto de Investigaciones Biomédicas (UCA-CONICET), Laboratorio de Patología Cardiovascular Experimental e Hipertensión Arterial, Buenos Aires, Argentina; Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - C Marotte
- Laboratorio de Metabolismo del Oxígeno INIGEM-UBA-CONICET, Buenos Aires, Argentina
| | - C Morales
- Departamento de Patología, Facultad de Medicina, Instituto de Fisiopatología Cardiovascular, Universidad de Buenos Aires, Argentina
| | - J Peralta
- Laboratorio de Metabolismo del Oxígeno INIGEM-UBA-CONICET, Buenos Aires, Argentina; Departamento de Medicina, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - G Berg
- Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - C Poderoso
- Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos Aires, Argentina
| | - J J Poderoso
- Laboratorio de Metabolismo del Oxígeno INIGEM-UBA-CONICET, Buenos Aires, Argentina
| | - M C Carreras
- Laboratorio de Metabolismo del Oxígeno INIGEM-UBA-CONICET, Buenos Aires, Argentina
| |
Collapse
|
9
|
Nascimento-Ferreira MV, Berg G, González Zapata LI, De Moraes ACF, Carvalho HB. Individualised prognosis for risk of developing abdominal obesity in the paediatric population. Clin Nutr ESPEN 2021; 45:333-340. [PMID: 34620337 DOI: 10.1016/j.clnesp.2021.07.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Revised: 07/20/2021] [Accepted: 07/23/2021] [Indexed: 11/19/2022]
Abstract
AIMS To develop and validate risk scores for predicting abdominal obesity in South American children and adolescents based on extrinsic and intrinsic variables. METHODS Children (n = 358) and adolescents (n = 369) from seven South American cities from the South American Youth Cardiovascular and Environmental (SAYCARE) Study. The primary outcome was abdominal obesity. Potential predictors were based on sociodemographic, maternal, environmental, and behavioural factors and nutritional status. In multilevel logistic models, associated variables were tested to build the scores, which were internally validated. RESULTS We identified 120 children and 98 adolescents who were abdominally obese. We found at least five variables associated with the outcome in children with unacceptable predictive capacity. However, in adolescents, we found that biological sex, age, maternal body mass index (BMI), active commuting by bike, soft drink consumption (for risk score A), and weight (for score B) can predict abdominal obesity. Both scores, A and B, showed acceptable performance in the ROC curve [areas under curve: 0.70 (95% CI: 0.56-0.82) and 0.95 (95% CI: 0.89-1.00), respectively]. CONCLUSION The SAYCARE risk scores present accurate, individualised estimates for identifying adolescents who are at risk of developing abdominal obesity. However, these have not been externally validated.
Collapse
Affiliation(s)
- Marcus Vinicius Nascimento-Ferreira
- YCARE (Youth/Child and Cardiovascular Risk and Environmental) Research Group, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Health, Physical Activity and Behavior ReseArch (Healthy-BRA) Group, Federal University of Tocantins, Miracema Do Tocantins, TO, Brazil.
| | - Gabriela Berg
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina.
| | - Laura Inés González Zapata
- Social and Economic Determinants of Health and Nutrition Research Group, School of Nutrition and Dietetics, University of Antioquia, Medellin, Colombia.
| | - Augusto César Ferreira De Moraes
- YCARE (Youth/Child and Cardiovascular Risk and Environmental) Research Group, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Department of Epidemiology, Graduate Program in Public Health and Graduate Program in Epidemiology School of Public Health, University of Sao Paulo, Sao Paulo, SP, Brazil; Department of Epidemiology, Human Genetics and Environmental Science (EHGES) of the School of Public Health, The University of Texas at Austin (UTHealth), USA.
| | - Heráclito Barbosa Carvalho
- YCARE (Youth/Child and Cardiovascular Risk and Environmental) Research Group, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
| |
Collapse
|
10
|
Corral P, Berg G, Zago V, Lopez G, Bursztyn M, Schreier L. Does remnants-like particle cholesterol is elevated in FH? Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Ibar C, Fortuna F, Gonzalez D, Jamardo J, Jacobsen D, Pugliese L, Giraudo L, Ceres V, Mendoza C, Repetto EM, Reboredo G, Iglesias S, Azzara S, Berg G, Zopatti D, Fabre B. Evaluation of stress, burnout and hair cortisol levels in health workers at a University Hospital during COVID-19 pandemic. Psychoneuroendocrinology 2021; 128:105213. [PMID: 33845387 PMCID: PMC8015376 DOI: 10.1016/j.psyneuen.2021.105213] [Citation(s) in RCA: 44] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 03/05/2021] [Accepted: 03/26/2021] [Indexed: 12/26/2022]
Abstract
UNLABELLED In the critical context of COVID-19 pandemic, healthcare workers are on the front line, participating directly in the care, diagnosis, and treatment of patients with COVID-19. This exposes them to a higher risk of developing chronic stress, psychological distress, and any other mental health symptoms. OBJECTIVE to evaluate stress and burnout in a health workers population and, in addition, to measure hair cortisol concentration as a current biomarker of stress. MATERIALS AND METHODS 234 health workers from Hospital de Clínicas "José de San Martín", Buenos Aires University, were included in this study. In this population hair samples were obtained from the posterior vertex as close to the scalp as possible and the individuals completed the following surveys: perceived stress, social support, burnout scale, life event scale, and sociodemographic data. Hair cortisol was measured by an automated chemiluminescent method. The studied population was divided into three groups considering those individuals below the healthy reference sample range (< 40 pg/mg hair), within the healthy reference range (40-128 pg/mg hair) and above the reference range (> 128 pg/mg hair). This study used a transversal and observational design. RESULTS Our results show that 40% of the studied population presented hair cortisol values outside of the healthy reference range. In the whole studied population, a direct correlation was found between hair cortisol concentration and perceived stress as well as between hair cortisol concentration and the emotional exhaustion component of burnout (r = 0.142, p = 0.030; r = 0.143, p = 0.029, respectively). 12% of the studied population showed Burnout (52% doctors and residents, 19% nurses, 19% administrative personnel). Higher values in hair cortisol levels were found in the group with burnout versus individuals without burnout (p = 0.034). Finally, a mediation analysis was performed, finding that depersonalization is a mediating variable in the relationship between self-perceived stress and hair cortisol level (F = 4.86, p = 0.0086; indirect effect IC: 0.0987-1.8840). CONCLUSION This is the first study in which a stress biomarker such as hair cortisol is evaluated in this population and in this context. Healthcare workers are subjected to increased levels of stress and burnout. High depersonalization, emotional exhaustion, and decreased personal sense of accomplishment characterize this population. It is the responsibility of the health authorities to implement strategies to manage this psychological emergency.
Collapse
Affiliation(s)
- Carolina Ibar
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Residencia en Bioquímica Clínica, Argentina,Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Buenos Aires, Argentina
| | - Federico Fortuna
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Residencia en Bioquímica Clínica, Argentina
| | - Diego Gonzalez
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Buenos Aires, Argentina,Universidad de Buenos Aires, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martin, Argentina,Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| | - Juan Jamardo
- Universidad de Buenos Aires, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martin, Argentina
| | - Dario Jacobsen
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Buenos Aires, Argentina,Universidad de Buenos Aires, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martin, Argentina
| | - Lucas Pugliese
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Buenos Aires, Argentina
| | - Laura Giraudo
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Residencia en Bioquímica Clínica, Argentina
| | - Veronica Ceres
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Residencia en Bioquímica Clínica, Argentina
| | - Cynthia Mendoza
- Universidad de Buenos Aires, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martin, Argentina
| | - Esteban M. Repetto
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Buenos Aires, Argentina,Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina
| | - Graciela Reboredo
- Universidad de Buenos Aires, Hospital de Clínicas José de San Martin, Área Ambulatoria del tratamiento y seguimiento del HIV-SIDA, Argentina
| | - Silvia Iglesias
- Cátedra de Química Analítica Instrumental, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Sergio Azzara
- Cátedra de Metodología para la Investigación Psicológica I, Facultad de Psicología, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Gabriela Berg
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Buenos Aires, Argentina,Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina,Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina
| | - Damian Zopatti
- Universidad de Buenos Aires, Facultad de Medicina, Dirección de Estadística y Archivo Médico, Hospital de Clínicas José de San Martin, Argentina
| | - Bibiana Fabre
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Buenos Aires, Argentina; Universidad de Buenos Aires, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martin, Argentina; Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina.
| |
Collapse
|
12
|
Del Mauro JS, Prince PD, Santander Plantamura Y, Allo MA, Parola L, Fernandez Machulsky N, Morettón MA, Bin EP, González GE, Bertera FM, Carranza A, Berg G, Taira CA, Donato M, Chiappetta DA, Polizio AH, Höcht C. Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats. Hypertens Res 2021; 44:791-802. [PMID: 33612826 DOI: 10.1038/s41440-021-00630-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2020] [Revised: 12/06/2020] [Accepted: 12/27/2020] [Indexed: 02/07/2023]
Abstract
β-Adrenergic blockers are no longer recommended as first-line therapy due to the reduced cardioprotection of traditional β-blockers compared with other antihypertensive drugs. It is unknown whether third-generation β-blockers share the limitations of traditional β-blockers. The aim of the present study was to compare the effects of nebivolol or atenolol on central and peripheral systolic blood pressure (SBP) and its variability and target organ damage (TOD) in N-nitro-L-arginine methyl ester (L-NAME) hypertensive rats. Male Wistar rats were treated with L-NAME for 8 weeks together with oral administration of nebivolol 30 mg/kg (n = 8), atenolol 90 mg/kg (n = 8), or vehicle (n = 8). The control group was composed of vehicle-treated Wistar rats. SBP and its variability, as well as echocardiographic parameters, were assessed during the last 2 weeks of treatment. Tissue levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and transforming growth factor β (TGF-β), and histopathological parameters were evaluated in the left ventricle and aorta. Nebivolol had a greater ability than atenolol to decrease central SBP and mid-term and short-term blood pressure variability (BPV) in L-NAME rats. Echocardiographic analysis showed that nebivolol was more effective than atenolol on E/A wave ratio normalization. Compared with atenolol treatment, nebivolol had a greater protective effect on different TOD markers, inducing a decrease in collagen deposition and a reduction in the proinflammatory cytokines IL-6 and TNF-α in the left ventricle and aorta. Our findings suggest that the adverse hemodynamic profile and the reduced cardiovascular protection reported with traditional β-blockers must not be carried forward to third-generation β-blockers.
Collapse
Affiliation(s)
- Julieta S Del Mauro
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Buenos Aires, Argentina.
| | - Paula D Prince
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Físicoquímica, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Buenos Aires, Argentina
| | - Yanina Santander Plantamura
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Buenos Aires, Argentina
| | - Miguel A Allo
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Buenos Aires, Argentina
| | - Luciano Parola
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Buenos Aires, Argentina
| | - Nahuel Fernandez Machulsky
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| | - Marcela A Morettón
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Tecnología Farmacéutica, Buenos Aires, Argentina
| | - Eliana P Bin
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Fisiopatología Cardiovascular (INFICA), Departamento de Patología, Buenos Aires, Argentina
| | - Germán E González
- Instituto de Investigaciones Biomédicas (BIOMED UCA-CONICET), Laboratorio de Patología Cardiovascular Experimental e Hipertensión Arterial, Buenos Aires, Argentina
| | - Facundo M Bertera
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| | - Andrea Carranza
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Buenos Aires, Argentina
| | - Gabriela Berg
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| | - Carlos A Taira
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| | - Martín Donato
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Fisiopatología Cardiovascular (INFICA), Departamento de Patología, Buenos Aires, Argentina
| | - Diego A Chiappetta
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Tecnología Farmacéutica, Buenos Aires, Argentina
| | - Ariel H Polizio
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Buenos Aires, Argentina
| | - Christian Höcht
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| |
Collapse
|
13
|
Ryan MJ, Schloter M, Berg G, Kostic T, Kinkel LL, Eversole K, Macklin JA, Schelkle B, Kazou M, Sarand I, Singh BK, Fischer D, Maguin E, Ferrocino I, Lima N, McClure RS, Charles TC, de Souza RSC, Kiran GS, Krug HL, Taffner J, Roume H, Selvin J, Smith D, Rybakova D, Sessitsch A. Development of Microbiome Biobanks - Challenges and Opportunities: (Trends in Microbiology 29, 89-92; 2021). Trends Microbiol 2021; 29:378. [PMID: 33573876 DOI: 10.1016/j.tim.2021.01.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Ibañez AE, Pasquevich MY, Machulsky NF, Berg G, Heras H, Montalti D, Grilli MG. Dynamics of circulating lipoproteins and lipids in Brown Skua (Stercorarius antarcticus lonnbergi) during the breeding cycle. Polar Biol 2021. [DOI: 10.1007/s00300-020-02793-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Corral P, Bañares V, Alves A, López G, Zago V, Martini J, Berg G, Bourbon M, Schreier L. LDL genetic risk score in patients with hypercholesterolemia to evaluate polygenic causes in Argentina. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
16
|
Suciu AAM, Gadermaier E, Wallwitz J, Berg G, Himmler G. Highly sensitive quantification of human total VEGF-A with a novel ELISA. Bone Rep 2020. [DOI: 10.1016/j.bonr.2020.100361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Corral P, Bañares V, Sáenz B, Zago V, Sarobe A, López G, Berg G, Schreier L. Phenotype of definite familial hypercholesterolemia with negative genetic study in Argentina. Arch Cardiol Mex 2020; 90:130-136. [PMID: 32897268 DOI: 10.24875/acme.m20000106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Objective Familial hypercholesterolemia (FH) is a monogenic disease, associated with variants in the LDLR, APOB and PCSK9 genes. The initial diagnosis is based on clinical criteria like the DLCN criteria. A score > 8 points qualifies the patient as "definite" for FH diagnosis. The detection of the presence of a variant in these genes allows carrying out familial cascade screening and better characterizes the patient in terms of prognosis and treatment. Methods In the context of the FH detection program in Argentina (Da Vinci Study) 246 hypercholesterolemic patients were evaluated, 21 with DLCN score > 8 (definite diagnosis).These patients were studied with next generation sequencing to detect genetic variants, with an extended panel of 23 genes; also they were adding the large rearrangements analysis and a polygenic score of 10 SNP (single nucleotide polymorphism) related to the increase in LDL-c. Results Of the 21 patients, 10 had variants in LDLR, 1 in APOB with APOE, 1 in LIPC plus elevated polygenic score, and 2 patients showed one deletion and one duplication in LDLR, the later with a variation in LIPA. It is highlighted that 6 of the 21 patients with a score > 8 did not show any genetic alteration. Conclusions We can conclude that 28% of the patients with definite clinical diagnosis of FH did not show genetic alteration. The possible explanations for this result would be the presence of mutations in new genes, confusing effects of the environment over the genes, the gene-gene interactions, and finally the impossibility of detecting variants with the current available methods.
Collapse
Affiliation(s)
- Pablo Corral
- Cátedra de Farmacología, Facultad de Medicina, Universidad FASTA. Buenos Aires, Argentina
| | - Virginia Bañares
- Departamento de Genética Experimental, Centro Nacional de Genética Medica "Dr. Eduardo Castilla", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos Malbran". Buenos Aires, Argentina
| | - Benjamín Sáenz
- Departamento de Investigación, Facultad de Medicina, Universidad FASTA. Buenos Aires, Argentina
| | - Valeria Zago
- Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Universidad de Buenos Aires, Laboratorio de Lípidos y Aterosclerosis, INFIBIOCUBA. Buenos Aires, Argentina
| | - Agustina Sarobe
- Cátedra de Farmacología, Facultad de Medicina, Universidad FASTA. Buenos Aires, Argentina
| | - Graciela López
- Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Universidad de Buenos Aires, Laboratorio de Lípidos y Aterosclerosis, INFIBIOCUBA. Buenos Aires, Argentina
| | - Gabriela Berg
- Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Universidad de Buenos Aires, Laboratorio de Lípidos y Aterosclerosis, INFIBIOCUBA. Buenos Aires, Argentina
| | - Laura Schreier
- Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Universidad de Buenos Aires, Laboratorio de Lípidos y Aterosclerosis, INFIBIOCUBA. Buenos Aires, Argentina
| |
Collapse
|
18
|
Ryan MJ, Schloter M, Berg G, Kostic T, Kinkel LL, Eversole K, Macklin JA, Schelkle B, Kazou M, Sarand I, Singh BK, Fischer D, Maguin E, Ferrocino I, Lima N, McClure RS, Charles TC, de Souza RSC, Kiran GS, Krug HL, Taffner J, Roume H, Selvin J, Smith D, Rybakova D, Sessitsch A. Development of Microbiome Biobanks - Challenges and Opportunities. Trends Microbiol 2020; 29:89-92. [PMID: 32800611 DOI: 10.1016/j.tim.2020.06.009] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 06/20/2020] [Accepted: 06/25/2020] [Indexed: 12/16/2022]
Abstract
The microbiome research field is rapidly evolving, but the required biobanking infrastructure is currently fragmented and not prepared for the biobanking of microbiomes. The rapid advancement of technologies requires an urgent assessment of how biobanks can underpin research by preserving microbiome samples and their functional potential.
Collapse
Affiliation(s)
| | - M Schloter
- Helmholtz Zentrum München, National Research Center for Environmental Health, Research Unit for Comparative Microbiome Analysis, Oberschleissheim, Germany
| | - G Berg
- Institute of Environmental Biotechnology, Graz University of Technology, Graz, Austria
| | - T Kostic
- AIT Austrian Institute of Technology, Center for Health and Bioresources, Bioresources Unit, Tulln, Austria
| | - L L Kinkel
- Department of Plant Pathology, University of Minnesota, Saint Paul, MN, USA
| | - K Eversole
- International Alliance for Phytobiomes Research, Lee's Summit, MO, USA; Eversole Associates, Bethesda, MD, USA
| | - J A Macklin
- Agriculture and Agri-Food Canada, Ottawa, ON, Canada
| | - B Schelkle
- European Food Information Council, Brussels, Belgium
| | - M Kazou
- Laboratory of Dairy Research, Department of Food Science and Human Nutrition, Agricultural University of Athens, Athens, Greece
| | - I Sarand
- Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia
| | - B K Singh
- Global Centre for Land Based Innovation, Hawkesbury Institute for the Environment, Western Sydney University, Penrith, Australia
| | - D Fischer
- Helmholtz Zentrum München, National Research Center for Environmental Health, Research Unit for Comparative Microbiome Analysis, Oberschleissheim, Germany
| | - E Maguin
- INRAE, MICALIS Institute, Metagenopolis, Jouy-en-Josas, France
| | - I Ferrocino
- Department of Agricultural, Forest and Food Science, University of Turin, Grugliasco, Italy
| | - N Lima
- Biological Engineering Centre, University of Minho, Braga, Portugal
| | - R S McClure
- Pacific Northwest National Laboratory, Richland, WA, USA
| | - T C Charles
- Waterloo Centre for Microbial Research, University of Waterloo, Waterloo, ON, Canada
| | - R S C de Souza
- Genomics for Climate Change Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
| | - G S Kiran
- Department of Food Science and Technology, Pondicherry University, Puducherry, India
| | - H L Krug
- Institute of Environmental Biotechnology, Graz University of Technology, Graz, Austria
| | - J Taffner
- Institute of Environmental Biotechnology, Graz University of Technology, Graz, Austria
| | - H Roume
- INRAE, MICALIS Institute, Metagenopolis, Jouy-en-Josas, France
| | - J Selvin
- Department of Microbiology, Pondicherry University, Puducherry, India
| | | | - D Rybakova
- Institute of Environmental Biotechnology, Graz University of Technology, Graz, Austria
| | - A Sessitsch
- AIT Austrian Institute of Technology, Center for Health and Bioresources, Bioresources Unit, Tulln, Austria
| |
Collapse
|
19
|
Corral P, Bañares V, Sáenz B, Zago V, Sarobe A, López G, Berg G, Schreier L. Fenotipo de hipercolesterolemia familiar definitivo con estudio genético negativo en Argentina. Arch Cardiol Mex 2020; 90:151-157. [PMID: 32459195 DOI: 10.24875/acm.19000221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Objective Familial hypercholesterolemia (FH) is a monogenic disease, associated with variants in the LDLR, APOB and PCSK9 genes. The initial diagnosis is based on clinical criteria like the DLCN criteria. A score > 8 points qualifies the patient as "definite" for FH diagnosis. The detection of the presence of a variant in these genes allows carrying out familial cascade screening and better characterizes the patient in terms of prognosis and treatment. Methods In the context of the FH detection program in Argentina (Da Vinci Study) 246 hypercholesterolemic patients were evaluated, 21 with DLCN score > 8 (definite diagnosis).These patients were studied with next generation sequencing to detect genetic variants, with an extended panel of 23 genes; also they were adding the large rearrangements analysis and a polygenic score of 10 SNP (single nucleotide polymorphism) related to the increase in LDL-c. Results Of the 21 patients, 10 had variants in LDLR, 1 in APOB with APOE, 1 in LIPC plus elevated polygenic score, and 2 patients showed one deletion and one duplication in LDLR, the later with a variation in LIPA. It is highlighted that 6 of the 21 patients with a score > 8 did not show any genetic alteration. Conclusions We can conclude that 28% of the patients with definite clinical diagnosis of FH did not show genetic alteration. The possible explanations for this result would be the presence of mutations in new genes, confusing effects of the environment over the genes, the gene-gene interactions, and finally the impossibility of detecting variants with the current available methods.
Collapse
Affiliation(s)
- Pablo Corral
- Facultad de Medicina, Cátedra de Farmacología, Universidad FASTA, Mar del Plata, Argentina
| | - Virginia Bañares
- Departamento de Genética Experimental, Centro Nacional de Genética Médica "Dr. Eduardo Castilla", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos Malbrán", Buenos Aires, Argentina
| | - Benjamín Sáenz
- Departamento de Investigación, Universidad FASTA, Mar del Plata, Argentina
| | - Valeria Zago
- Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Laboratorio de Lípidos y Aterosclerosis, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Agustina Sarobe
- Facultad de Medicina, Cátedra de Farmacología, Universidad FASTA, Mar del Plata, Argentina
| | - Graciela López
- Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Laboratorio de Lípidos y Aterosclerosis, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Gabriela Berg
- Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Laboratorio de Lípidos y Aterosclerosis, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Laura Schreier
- Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Laboratorio de Lípidos y Aterosclerosis, Universidad de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
20
|
Cassaglia P, Penas F, Betazza C, Fontana Estevez F, Miksztowicz V, Martínez Naya N, Llamosas MC, Noli Truant S, Wilensky L, Volberg V, Cevey ÁC, Touceda V, Cicale E, Berg G, Fernández M, Goren N, Morales C, González GE. Genetic Deletion of Galectin-3 Alters the Temporal Evolution of Macrophage Infiltration and Healing Affecting the Cardiac Remodeling and Function after Myocardial Infarction in Mice. Am J Pathol 2020; 190:1789-1800. [PMID: 32473918 DOI: 10.1016/j.ajpath.2020.05.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 04/22/2020] [Accepted: 05/05/2020] [Indexed: 12/13/2022]
Abstract
We studied the role of galectin-3 (Gal-3) in the expression of alternative activation markers (M2) on macrophage, cytokines, and fibrosis through the temporal evolution of healing, ventricular remodeling, and function after myocardial infarction (MI). C57BL/6J and Gal-3 knockout mice (Lgals3-/-) were subjected to permanent coronary ligation or sham. We studied i) mortality, ii) macrophage infiltration and expression of markers of alternative activation, iii) cytokine, iv) matrix metalloproteinase-2 activity, v) fibrosis, and vi) cardiac function and remodeling. At 1 week post-MI, lack of Gal-3 markedly attenuated F4/80+ macrophage infiltration and significantly increased the expression of Mrc1 and Chil1, markers of M2 macrophages at the MI zone. Levels of IL-10, IL-6, and matrix metalloproteinase-2 were significantly increased, whereas tumor necrosis factor-α, transforming growth factor-β, and fibrosis were remarkably attenuated at the infarct zone. In Gal-3 knockout mice, scar thinning ratio, expansion, and cardiac remodeling and function were severely affected from the onset of MI. At 4 weeks post-MI, the natural evolution of fibrosis in Gal-3 knockout mice was also affected. Our results suggest that Gal-3 is essential for wound healing because it regulates the dynamics of macrophage infiltration, proinflammatory and anti-inflammatory cytokine expression, and fibrosis along the temporal evolution of MI in mice. The deficit of Gal-3 affected the dynamics of wound healing, thus aggravating the evolution of remodeling and function.
Collapse
Affiliation(s)
- Pablo Cassaglia
- Facultad de Medicina-CONICET, Departamento de Patología, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina
| | - Federico Penas
- Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Buenos Aires, Argentina
| | - Celeste Betazza
- Facultad de Medicina-CONICET, Departamento de Patología, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina; Facultad de Medicina, Pontificia Universidad Católica Argentina (UCA), Instituto de Investigaciones Biomédicas (UCA-CONICET), Laboratorio de Patología Cardiovascular Experimental e Hipertensi Arterial, Buenos Aires, Argentina
| | - Florencia Fontana Estevez
- Facultad de Medicina, Pontificia Universidad Católica Argentina (UCA), Instituto de Investigaciones Biomédicas (UCA-CONICET), Laboratorio de Patología Cardiovascular Experimental e Hipertensi Arterial, Buenos Aires, Argentina
| | - Verónica Miksztowicz
- Facultad de Medicina, Pontificia Universidad Católica Argentina (UCA), Instituto de Investigaciones Biomédicas (UCA-CONICET), Laboratorio de Patología Cardiovascular Experimental e Hipertensi Arterial, Buenos Aires, Argentina; Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica-INFIBIOC, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina
| | - Nadia Martínez Naya
- Facultad de Medicina-CONICET, Departamento de Patología, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina
| | - María Clara Llamosas
- Facultad de Medicina-CONICET, Departamento de Patología, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina
| | - Sofía Noli Truant
- Facultad de Farmacia y Bioquímica-CONICET, Instituto de Estudios de la Inmunidad Humoral (IDEHU), Buenos Aires, Argentina
| | - Luciana Wilensky
- Facultad de Medicina-CONICET, Departamento de Patología, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina
| | - Verónica Volberg
- Facultad de Medicina-CONICET, Departamento de Patología, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina
| | - Ágata C Cevey
- Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Buenos Aires, Argentina
| | - Vanessa Touceda
- Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica-INFIBIOC, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina
| | - Eliana Cicale
- Facultad de Ciencias Veterinarias, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Gabriela Berg
- Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica-INFIBIOC, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina
| | - Marisa Fernández
- Facultad de Farmacia y Bioquímica-CONICET, Instituto de Estudios de la Inmunidad Humoral (IDEHU), Buenos Aires, Argentina
| | - Nora Goren
- Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Buenos Aires, Argentina
| | - Celina Morales
- Facultad de Medicina-CONICET, Departamento de Patología, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina
| | - Germán E González
- Facultad de Medicina-CONICET, Departamento de Patología, Instituto de Fisiopatología Cardiovascular, Buenos Aires, Argentina; Facultad de Medicina, Pontificia Universidad Católica Argentina (UCA), Instituto de Investigaciones Biomédicas (UCA-CONICET), Laboratorio de Patología Cardiovascular Experimental e Hipertensi Arterial, Buenos Aires, Argentina.
| |
Collapse
|
21
|
Barchuk M, Dutour A, Ancel P, Svilar L, Miksztowicz V, Lopez G, Rubio M, Schreier L, Nogueira JP, Valéro R, Béliard S, Martin JC, Berg G, Gaborit B. Untargeted Lipidomics Reveals a Specific Enrichment in Plasmalogens in Epicardial Adipose Tissue and a Specific Signature in Coronary Artery Disease. Arterioscler Thromb Vasc Biol 2020; 40:986-1000. [PMID: 32102570 DOI: 10.1161/atvbaha.120.313955] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
OBJECTIVE Epicardial adipose tissue (EAT) is an active endocrine organ that could contribute to the pathophysiology of coronary artery disease (CAD) through the paracrine release of proatherogenic mediators. Numerous works have analyzed the inflammatory signature of EAT, but scarce informations on its lipidome are available. Our objective was first to study the differences between EAT and subcutaneous adipose tissue (SAT) lipidomes and second to identify the specific untargeted lipidomic signatures of EAT and SAT in CAD. Approach and Results: Subcutaneous and EAT untargeted lipidomic analysis was performed in 25 patients with CAD and 14 patients without CAD and compared with paired plasma lipidomic analysis of isolated VLDL (very low-density lipoprotein) and HDL (high-density lipoprotein). Lipidomics was performed on a C18 column hyphenated to a Q-Exactive plus mass spectrometer, using both positive and negative ionization mode. EAT and SAT had independent lipidomic profile, with 95 lipid species differentially expressed and phosphatidylethanolamine 18:1p/22:6 twenty-fold more expressed in EAT compared with SAT false discovery rate =3×10-4). Patients with CAD exhibited more ceramides (P=0.01), diglycerides (P=0.004; saturated and nonsaturated), monoglycerides (P=0.013) in their EAT than patients without CAD. Conversely, they had lesser unsaturated TG (triglycerides; P=0.02). No difference was observed in the 295 lipid species found in SAT between patients with and without CAD. Fifty-one lipid species were found in common between EAT and plasma lipoproteins. TG 18:0/18:0/18:1 was found positively correlated (r=0.45, P=0.019) in EAT and HDL and in EAT and VLDL (r=0.46, P=0.02). CONCLUSIONS CAD is associated with specific lipidomic signature of EAT, unlike SAT. Plasma lipoprotein lipidome only partially reflected EAT lipidome.
Collapse
Affiliation(s)
- Magali Barchuk
- From the Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina (M.B., V.M., G.L., L.S., G.B.)
| | - Anne Dutour
- Aix-Marseille University, INSERM, INRAE, C2VN, France (A.D., P.A., L.S., R.V., S.B., J.C.M., B.G.).,Endocrinology, Metabolic Diseases and Nutrition Department, Assistance Publique Hôpitaux de Marseille, France (A.D., R.V., S.B., B.G.)
| | - Patricia Ancel
- Aix-Marseille University, INSERM, INRAE, C2VN, France (A.D., P.A., L.S., R.V., S.B., J.C.M., B.G.)
| | - Ljubica Svilar
- Aix-Marseille University, INSERM, INRAE, C2VN, France (A.D., P.A., L.S., R.V., S.B., J.C.M., B.G.).,CRIBIOM, Criblage Biologique Marseille, Faculté de Medecine de la Timone, France (L.S.)
| | - Veronica Miksztowicz
- From the Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina (M.B., V.M., G.L., L.S., G.B.).,Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Argentina (V.M., G.B.)
| | - Graciela Lopez
- From the Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina (M.B., V.M., G.L., L.S., G.B.)
| | - Miguel Rubio
- Universidad de Buenos Aires, Hospital de Clínicas "José de San Martín", División de Cirugía Cardiovascular, Argentina (M.R.)
| | - Laura Schreier
- From the Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina (M.B., V.M., G.L., L.S., G.B.)
| | - Juan Patricio Nogueira
- Servicio de Docencia e Investigación, Hospital Central de Formosa, Facultad de Ciencias de la Salud, Universidad Nacional de Formosa, Argentina (J.P.N.)
| | - René Valéro
- Aix-Marseille University, INSERM, INRAE, C2VN, France (A.D., P.A., L.S., R.V., S.B., J.C.M., B.G.).,Endocrinology, Metabolic Diseases and Nutrition Department, Assistance Publique Hôpitaux de Marseille, France (A.D., R.V., S.B., B.G.)
| | - Sophie Béliard
- Aix-Marseille University, INSERM, INRAE, C2VN, France (A.D., P.A., L.S., R.V., S.B., J.C.M., B.G.).,Endocrinology, Metabolic Diseases and Nutrition Department, Assistance Publique Hôpitaux de Marseille, France (A.D., R.V., S.B., B.G.)
| | - Jean Charles Martin
- Aix-Marseille University, INSERM, INRAE, C2VN, France (A.D., P.A., L.S., R.V., S.B., J.C.M., B.G.)
| | - Gabriela Berg
- From the Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina (M.B., V.M., G.L., L.S., G.B.).,Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Argentina (V.M., G.B.)
| | - Bénédicte Gaborit
- Aix-Marseille University, INSERM, INRAE, C2VN, France (A.D., P.A., L.S., R.V., S.B., J.C.M., B.G.).,Endocrinology, Metabolic Diseases and Nutrition Department, Assistance Publique Hôpitaux de Marseille, France (A.D., R.V., S.B., B.G.)
| |
Collapse
|
22
|
Corral P, Geller AS, Polisecki EY, Lopez GI, Bañares VG, Cacciagiu L, Berg G, Hegele RA, Schaefer EJ, Schreier LE. Unusual genetic variants associated with hypercholesterolemia in Argentina. Atherosclerosis 2019; 277:256-261. [PMID: 30270055 DOI: 10.1016/j.atherosclerosis.2018.06.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 05/17/2018] [Accepted: 06/07/2018] [Indexed: 12/18/2022]
Abstract
BACKGROUND AND AIMS Marked hypercholesterolemia, defined as low density lipoprotein cholesterol (LDL-C) levels ≥ 190 mg/dL, may be due to LDLR, APOB, and PCSK9 variants. In a recent analysis, only 1.7% of cases had such variants. Our goal was to identify other potential genetic causes of hypercholesterolemia. METHODS In a total of 51,253 subjects with lipid testing, 3.8% had elevated total cholesterol >300 mg/dL and/or LDL-C≥190 mg/dL. Of these, 246 were further studied, and 69 without kidney, liver, or thyroid disease and who met Dutch Lipid Clinic Network criteria of ≥6 points had DNA sequencing done at the LDLR, APOB, PCSK9, APOE, LDLRAP1, STAP1, ABCG5, ABCG8, CYP27A1, LIPA, LIPC, LIPG, LPL, and SCARB1 gene loci and also had 10 SNP analysis for a weighted high LDL-C genetic risk score. RESULTS In the 69 subjects with genetic analyses, the following variants were observed in 37 subjects (53.6%): LDLR (n = 20, 2 novel), ABCG5/8 (n = 7, 2 novel), APOB (n = 3, 1 novel), CYP27A1 (n = 3, 1 novel), LIPA (n = 2, 1 novel), APOE (n = 2), LIPC (n = 1, novel), LIPG (n = 1, novel), and SCARB1 (n = 1); 14 subjects (20.3%) had a high polygenic score, with 4 (5.8%) having no variants. CONCLUSIONS Our data indicate that in addition to variants in LDLR, APOB, PCSK9, APOE, LDLRAP1, and STAP1, variants in ABCG5/8, CYP27A1, LIPA, LIPC, and LIPG may be associated with hypercholesterolemia and such information should be used to optimize therapy.
Collapse
Affiliation(s)
- Pablo Corral
- Departamento de Investigación, Facultad de Medicina, Universidad FASTA, Buenos Aires, Argentina
| | | | | | - Graciela I Lopez
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, INFIBIOC-UBA, Buenos Aires, Argentina
| | - Virginia G Bañares
- Departamento de Genética Experimental, Centro Nacional de Genética Médica "Dr Eduardo Castilla", Administración Nacional de Laboratorios e Institutos de Salud "Dr Carlos Malbrán", Buenos Aires, Argentina
| | - Leonardo Cacciagiu
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, INFIBIOC-UBA, Buenos Aires, Argentina
| | - Gabriela Berg
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, INFIBIOC-UBA, Buenos Aires, Argentina
| | - Robert A Hegele
- Robarts Research Institute, University Western Ontario, London, Ontario, Canada
| | | | - Laura E Schreier
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, INFIBIOC-UBA, Buenos Aires, Argentina.
| |
Collapse
|
23
|
Lobmaier SM, Müller A, Zelgert C, Shen C, Su PC, Schmidt G, Haller B, Berg G, Fabre B, Weyrich J, Wu HT, Frasch MG, Antonelli MC. Fetal heart rate variability responsiveness to maternal stress, non-invasively detected from maternal transabdominal ECG. Arch Gynecol Obstet 2019; 301:405-414. [PMID: 31781889 DOI: 10.1007/s00404-019-05390-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Accepted: 11/14/2019] [Indexed: 10/25/2022]
Abstract
PURPOSE Prenatal stress (PS) during pregnancy affects in utero- and postnatal child brain-development. Key systems affected are the hypothalamic-pituitary-adrenal axis and the autonomic nervous system (ANS). Maternal- and fetal ANS activity can be gauged non-invasively from transabdominal electrocardiogram (taECG). We propose a novel approach to assess couplings between maternal (mHR) and fetal heart rate (fHR) as a new biomarker for PS based on bivariate phase-rectified signal averaging (BPRSA). We hypothesized that PS exerts lasting impact on fHR. METHODS Prospective case-control study matched for maternal age, parity, and gestational age during the third trimester using the Cohen Perceived Stress Scale (PSS-10) questionnaire with PSS-10 over or equal 19 classified as stress group (SG). Women with PSS-10 < 19 served as control group (CG). Fetal electrocardiograms were recorded by a taECG. Coupling between mHR and fHR was analyzed by BPRSA resulting in fetal stress index (FSI). Maternal hair cortisol, a memory of chronic stress exposure for 2-3 months, was measured at birth. RESULTS 538/1500 pregnant women returned the questionnaire, 55/538 (10.2%) mother-child pairs formed SG and were matched with 55/449 (12.2%) consecutive patients as CG. Maternal hair cortisol was 86.6 (48.0-169.2) versus 53.0 (34.4-105.9) pg/mg (p = 0.029). At 36 + 5 weeks, FSI was significantly higher in fetuses of stressed mothers when compared to controls [0.43 (0.18-0.85) versus 0.00 (- 0.49-0.18), p < 0.001]. CONCLUSION Prenatal maternal stress affects the coupling between maternal and fetal heart rate detectable non-invasively a month prior to birth. Lasting effects on neurodevelopment of affected offspring should be studied. TRIAL REGISTRATION Clinical trial registration: NCT03389178.
Collapse
Affiliation(s)
- Silvia M Lobmaier
- Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
| | - A Müller
- Innere Medizin I, Department of Cardiology, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany
| | - C Zelgert
- Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - C Shen
- Department of Mathematics, Duke University, Durham, NC, 27705, USA
| | - P C Su
- Department of Mathematics, Duke University, Durham, NC, 27705, USA
| | - G Schmidt
- Innere Medizin I, Department of Cardiology, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany
| | - B Haller
- Institute of Medical Informatics, Statistics and Epidemiology, Buenos Aires, Argentina
| | - G Berg
- Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET), Facultad de Farmacia Y Bioquímica, Buenos Aires, Argentina
| | - B Fabre
- Facultad de Farmacia Y Bioquímica. Instituto de Fisiopatología Y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires, Argentina
| | - J Weyrich
- Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - H T Wu
- Department of Mathematics, Duke University, Durham, NC, 27705, USA.,Department of Statistical Science, Duke University, Durham, NC, 27705, USA.,Mathematics Division, National Center for Theoretical Sciences, Taipei, Taiwan
| | - M G Frasch
- Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA
| | - M C Antonelli
- Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.,Instituto de Biología Celular Y Neurociencia "Prof. E. De Robertis", Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
24
|
Gonzalez G, Cassaglia PD, Penas F, Martinez NL, Bettazza C, Wilensky L, Fontana Estevez F, Noli Truant S, Miksztowicz V, Cevey A, Cicale E, Berg G, Fernandez M, Goren N, Morales C. P6297Genetic mutation of galectin-3 altered the temporal evolution of macrophage polarization and healing affecting the post myocardial infarct remodeling in mice. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Myocardial infarction (MI) is a dynamic process that leads to ventricular remodeling (VR) and largely to heart failure (HF). Previous studies established that Galectin-3 (Gal-3) is highly increased in the infarct zone from the beginning of MI and also that it is a prognostic marker of HF.
Purpose
We aimed to study the effects of genetic deletion of Gal-3 on macrophage (MΦ) infiltration, cytokines expression, fibrosis and MMP-2 activity as well as VR and function after MI in mice.
Methods
Male C57BL/6J and Gal-3 KO mice were subjected to permanent coronary ligature or sham. At 1 week post-MI LV function and VR were studied by echocardiography. We also studied in the infarct zone: 1) F4/80+ MΦ infiltration by flow cytometry; 2) M2 macrophage polarization by detection of mannose receptor (MR) and chitinase-3-like protein-3 (YM1) phenotype markers by rt-qPCR; 3) mRNA expression of TNF-α, IL-6, IL-10 and TGF-β; 4) MMP-2 activity by zymography and 5) fibrosis by histology.
Results
Results are expressed as X±SEM; *p<0.05 C57 MI vs Gal-3 KO MI. After 1 week post-MI, the pulmonary congestion assessed by the lung weight/body weight ratio (mg/g) was 9±0.4, 8±0.5 and 9±0.4 in C57 sham, Gal-3 KO sham and C57 MI, respectively, nevertheless it was severely increased to 15±1.2* in infarcted Gal-3 KO mice. MΦ infiltration, cytokine expression and MMP-2 activity in the infarct zone are shown in the table.
Table 1 Groups F4/80+ MR YM1 TNF-α IL-6 IL-10 TGF-β MMP-2 MΦ (%) (A.U.) (A.U.) (A.U.) (A.U.) (A.U.) (A.U.) (A.U.) C57 MI 5.6±0.9 (8) 0.5±0.2 (3) 1.7±0.4 (3) 26±0.3 (3) 1.7±0.5 (3) 0.7±0.03 (3) 1.8±0.5 (3) 1±0.1 (5) Gal-3 KO MI 2.6±0.4* (8) 1.8±0.4*(8) 4.2±0.4* (8) 0.4±0.5* (8) 6.7±0.9 * (8) 2.8±0.3 * (8) 0.5±0.2 * (8) 2±0.4* (6) A.U.: Arbitrary units. In MR, YM1, TNF-α, IL-6, IL-10 and TGF-β represent mRNA expression. In MMP-2 represent gelatinolytic activity. Number of samples is shown between parentheses.
After 1 week post-MI, LV end diastolic dimension was increased from 4.4±0.1 to 4.8±0.2* at the same time that ejection fraction (%) was significantly reduced from 47±2 to 38±3* in C57+MI (13) and Gal-3 KO+MI (16) respectively. Collagen concentration in the infarct zone was significantly reduced from 30±1.2% (6) to 17±0.5* % (8) in C57 and Gal-3 KO respectively.
Conclusion(s)
Gal-3 is an essential regulatory factor for the early wound healing since it regulates the dynamics of the reparative process through the phenotypic profile of MΦ, the pro- and anti-inflammatory cytokines expression and fibrosis along the temporal evolution of MI in mice. The deficit of Gal-3 diminished the infiltration of MΦ altering its phenotypic polarization and consequently, the dynamics of the wound healing as well as aggravating the functional and structural evolution of cardiac remodeling.
Acknowledgement/Funding
Argentine Agency for Promotion of Science and Technology (PICT 2014-2320), University of Buenos Aires (UBACyT 20020170100619BA)
Collapse
Affiliation(s)
- G Gonzalez
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - P D Cassaglia
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - F Penas
- University of Buenos Aires, Institute of Biomedical Research in Retrovirus and Aids, Capital Federal, Argentina
| | - N L Martinez
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - C Bettazza
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - L Wilensky
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| | - F Fontana Estevez
- Pontifical Catholic University of Argentina, Biomedical Research Institute (BIOMED), Capital Federal, Argentina
| | - S Noli Truant
- University of Buenos Aires, Institute for studies of humoral immunity, Buenos Aires, Argentina
| | - V Miksztowicz
- University of Buenos Aires. Faculty of Pharmacy and Biochemistry, Lipids Laboratory, Capital Federal, Argentina
| | - A Cevey
- University of Buenos Aires, Institute of Biomedical Research in Retrovirus and Aids, Capital Federal, Argentina
| | - E Cicale
- University of Buenos Aires. Faculty of Veterinary, bioresources, Capital Federal, Argentina
| | - G Berg
- University of Buenos Aires. Faculty of Pharmacy and Biochemistry, Lipids Laboratory, Capital Federal, Argentina
| | - M Fernandez
- University of Buenos Aires, Institute for studies of humoral immunity, Buenos Aires, Argentina
| | - N Goren
- University of Buenos Aires, Institute of Biomedical Research in Retrovirus and Aids, Capital Federal, Argentina
| | - C Morales
- University of Buenos Aires-CONICET. Faculty of Medicine, Institute of Cardiovascular Pathophysiology, Pathology, Capital Federal, Argentina
| |
Collapse
|
25
|
Barchuk M, Schreier L, López G, Cevey A, Baldi J, Fernandez Tomé MDC, Goren N, Rubio M, Miksztowicz V, Berg G. Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 and angiopoietin-like protein 4 are associated with the increase of lipoprotein lipase activity in epicardial adipose tissue from diabetic patients. Atherosclerosis 2019; 288:51-59. [DOI: 10.1016/j.atherosclerosis.2019.06.915] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Revised: 05/27/2019] [Accepted: 06/27/2019] [Indexed: 12/28/2022]
|
26
|
Rasmark Roepke E, Bruno V, Nedstrand E, Boij R, Strid CP, Piccione E, Berg G, Svensson-Arvelund J, Jenmalm MC, Rubér M, Ernerudh J. Low-molecular-weight-heparin increases Th1- and Th17-associated chemokine levels during pregnancy in women with unexplained recurrent pregnancy loss: a randomised controlled trial. Sci Rep 2019; 9:12314. [PMID: 31444404 PMCID: PMC6707182 DOI: 10.1038/s41598-019-48799-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Accepted: 08/13/2019] [Indexed: 11/29/2022] Open
Abstract
Low-molecular-weight heparin (LMWH) is widely used to treat recurrent pregnancy loss (RPL) because of its anti-coagulant effects. Although in vitro studies have suggested additional immunological effects, these are debated. We therefore investigated whether LMWH could modulate immune responses in vivo during pregnancy of women with unexplained RPL. A Swedish open multi-centre randomised controlled trial included 45 women treated with tinzaparin and 42 untreated women. Longitudinally collected plasma samples were obtained at gestational weeks (gw) 6, 18, 28 and 34 and analysed by multiplex bead technology for levels of 11 cytokines and chemokines, chosen to represent inflammation and T-helper subset-associated immunity. Mixed linear models test on LMWH-treated and untreated women showed differences during pregnancy of the Th1-associated chemokines CXCL10 (p = 0.01), CXCL11 (p < 0.001) and the Th17-associated chemokine CCL20 (p = 0.04), while CCL2, CCL17, CCL22, CXCL1, CXCL8, CXCL12, CXCL13 and IL-6 did not differ. Subsequent Student's t-test showed significantly higher plasma levels of CXCL10 and CXCL11 in treated than untreated women at gw 28 and 34. The consistent increase in the two Th1-associated chemokines suggests a potential proinflammatory and unfavourable effect of LMWH treatment during later stages of pregnancy, when Th1 immunity is known to disrupt immunological tolerance.
Collapse
Affiliation(s)
- E Rasmark Roepke
- Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö and Lund University, Lund, Sweden.
| | - V Bruno
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
- Section of Gynecology and Obstetrics, Academic Department of Biomedicine and Prevention, and Clinical Department of Surgery, Tor Vergata University Hospital, Rome, Italy
| | - E Nedstrand
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - R Boij
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - C Petersson Strid
- Departmen of Obstetrics and Gynecology, Kalmar Hospital, Kalmar, Sweden
| | - E Piccione
- Section of Gynecology and Obstetrics, Academic Department of Biomedicine and Prevention, and Clinical Department of Surgery, Tor Vergata University Hospital, Rome, Italy
| | - G Berg
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - J Svensson-Arvelund
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - M C Jenmalm
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - M Rubér
- Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| | - J Ernerudh
- Department of Clinical Immunology and Transfusion Medicine, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
| |
Collapse
|
27
|
Brocco MA, González MA, Frasch MG, Rumi M, Rey P, Pupelis L, Petzil E, Binda MV, Berg G, Fabre B, Susacasa S, Antonelli MC. Perceived maternal stress during pregnancy affects newborn development in a low-income cohort of pregnant women. Placenta 2019. [DOI: 10.1016/j.placenta.2019.06.236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Schreier L, Zago V, Cacciagiú L, Bursztyn M, Bañares V, López G, Berg G, Corral P. Are high levels of lp(a) associated with familial hypercholesterolemia? Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
29
|
Gadermaier E, Tesarz M, Wallwitz J, Berg G, Himmler G. Characterization of a sandwich ELISA for quantification of total human soluble neuropilin-1. J Clin Lab Anal 2019; 33:e22944. [PMID: 31219204 PMCID: PMC6757120 DOI: 10.1002/jcla.22944] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Accepted: 05/17/2019] [Indexed: 01/29/2023] Open
Abstract
Background Neuropilin‐1 (NRP1) is a highly interactive molecule that exists as transmembrane and soluble isoforms. Measurement of circulating levels of soluble NRP1 (sNRP1) in human serum and plasma has proven to be difficult due to present matrix interferences and due to the lack of a reliable technique. Methods We developed a highly specific and sensitive sandwich ELISA assay for total sNRP1 quantification in peripheral blood, and we validated the test according to ICH guidelines. The linear epitopes of the employed polyclonal and monoclonal anti‐human NRP1 antibodies were mapped with microarray technology. We included a sample pre‐treatment step with guanidine hydrochloride (GuHCl) to release sNRP1 from existing interferants. Results The ELISA assay which is calibrated with sNRP1 isoform 2 and covers a calibration range from 0.375 to 12 nmol/L detects sNRP1 in human serum and plasma (heparin, EDTA, and citrate). Multiple linear epitopes recognized by the polyclonal coating antibody are distributed over the whole sNRP1 sequence. The monoclonal detection antibody binds to a linear epitope which is in the N‐terminal region of the a1 domain of human sNRP1. Assay parameters like precision (intra‐assay: 6%), dilution linearity (95%‐115%), specificity (98%), and spike recovery (81%‐109%) meet the international standards of acceptance. Conclusion Our novel sandwich ELISA provides a reliable tool for the quantitative determination of total human sNRP1. The assay detects free and previous ligand‐bound total NRP1.
Collapse
|
30
|
Tesarz M, Gadermaier E, Wallwitz J, Berg G, Himmler G. SP283DESCRIPTION OF A VALIDATED SANDWICH ELISA FOR THE QUANTIFICATION OF TOTAL SOLUBLE HUMAN NEUROPILIN-1. Nephrol Dial Transplant 2019. [DOI: 10.1093/ndt/gfz103.sp283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | | | - Gabriela Berg
- Biomedica Medizinprodukte GmbH, Vienna, Austria, Austria
| | | |
Collapse
|
31
|
Betazza MC, Estevez FF, Cassaglia P, Wilensky L, Cozzi M, Truant SN, Miksztowicz V, Fernandez M, Naya NLM, Volberg V, Berg G, Casanova V, Morales C, Gonzalez GE. The lack of Galectin 3 modifies the evolution of the healing and post‐ myocardial infarct remodeling in mice. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.496.64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Maria Celeste Betazza
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Florencia Fontana Estevez
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Pablo Cassaglia
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Luciana Wilensky
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Maria Cozzi
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Sofia Noli Truant
- Instituto de Estudios de la Inmunidad HumoralFacultad de Farmacia y BioquimicaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Veronica Miksztowicz
- Instituto de Estudios de la Inmunidad HumoralFacultad de Farmacia y BioquimicaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Marisa Fernandez
- Instituto de Estudios de la Inmunidad HumoralFacultad de Farmacia y BioquimicaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Nadia Laura Martinez Naya
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Veronica Volberg
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Gabriela Berg
- Instituto de Estudios de la Inmunidad HumoralFacultad de Farmacia y BioquimicaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Veronica Casanova
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| | - Celina Morales
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| | - German Esteban Gonzalez
- Instituto de Fisiopatología CardiovascularFacultad de MedicinaUniversidad de Buenos AiresBuenos AiresArgentina
| |
Collapse
|
32
|
Berg G, Barchuk M, Miksztowicz V. Behavior of Metalloproteinases in Adipose Tissue, Liver and Arterial Wall: An Update of Extracellular Matrix Remodeling. Cells 2019; 8:cells8020158. [PMID: 30769840 PMCID: PMC6406870 DOI: 10.3390/cells8020158] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Revised: 01/22/2019] [Accepted: 02/01/2019] [Indexed: 02/06/2023] Open
Abstract
Extracellular matrix (ECM) remodeling is required for many physiological and pathological processes. Metalloproteinases (MMPs) are endopeptidases which are able to degrade different components of the ECM and nucleus matrix and to cleave numerous non-ECM proteins. Among pathological processes, MMPs are involved in adipose tissue expansion, liver fibrosis, and atherosclerotic plaque development and vulnerability. The expression and the activity of these enzymes are regulated by different hormones and growth factors, such as insulin, leptin, and adiponectin. The controversial results reported up to this moment regarding MMPs behavior in ECM biology could be consequence of the different expression patterns among species and the stage of the studied pathology. The aim of the present review was to update the knowledge of the role of MMPs and its inhibitors in ECM remodeling in high incidence pathologies such as obesity, liver fibrosis, and cardiovascular disease.
Collapse
Affiliation(s)
- Gabriela Berg
- Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
- Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
- Facultad de Farmacia y Bioquímica, CONICET, Universidad de Buenos Aires, Buenos Aires C1425FQB, Argentina.
| | - Magalí Barchuk
- Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
- Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
| | - Verónica Miksztowicz
- Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
- Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
- Facultad de Farmacia y Bioquímica, CONICET, Universidad de Buenos Aires, Buenos Aires C1425FQB, Argentina.
| |
Collapse
|
33
|
Machulsky NF, Barchuk M, Gagliardi J, Gonzalez D, Lombardo M, Escudero AG, Gigena G, Blanco F, Schreier L, Fabre B, Berg G. Vitamin D is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction. Curr Vasc Pharmacol 2019; 16:355-360. [PMID: 28595560 DOI: 10.2174/1570161115666170609102506] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Revised: 05/19/2017] [Accepted: 05/28/2017] [Indexed: 11/22/2022]
Abstract
BACKGROUND Vitamin D is a fat soluble vitamin involved in calcium and bone metabolism; recently its deficiency has been related to cardiovascular disease. In cardiac tissue, vitamin D suppresses metalloproteinases (MMPs) expression, enzymes directly associated with vulnerable plaque. OBJECTIVE To investigate whether the association between vitamin D and leptin is related to markers of vulnerable plaque, such as MMPs in patients with acute myocardial infarction. METHODS We studied 66 male patients with acute myocardial infarction, undergoing primary angioplasty. Blood samples were obtained at admission and 24hs after the surgery. Leptin and vitamin D concentrations in serum and MMP-2 and -9 activities in plasma were determined. RESULTS MMP-2 activity was increased in Vitamin D deficient/insufficient patients at admission (p=0.04) and 24 hs later (p=0.05). In a linear regression model, vitamin D explained 24% of the variance of MMP-2 activity (F=2.839 p=0.04). At admission, vitamin D correlated with serum leptin (r=-0.302 p=0.033), and explained 39.5% of its variation (F=4.432 p=0.003). CONCLUSION In the studied population, vitamin D was inversely related to MMP-2 and leptin which are involved in coronary artery disease and acute myocardial infarction. The decrease in this hormone levels would be associated with a worse metabolic profile in acute coronary syndrome patients.
Collapse
Affiliation(s)
- Nahuel Fernandez Machulsky
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Departamento de Bioquimica Clinica, Catedra de Bioquimica Clinica I, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Instituto de Fisiopatologia y Bioquimica Clinica (INFIBIOC), Buenos Aires, Argentina
| | - Magali Barchuk
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Departamento de Bioquimica Clinica, Catedra de Bioquimica Clinica I, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Instituto de Fisiopatologia y Bioquimica Clinica (INFIBIOC), Buenos Aires, Argentina
| | - Juan Gagliardi
- Hospital General Doctor Cosme Argerich, Division de Cardiologia, Unidad de Hemodinamia, Buenos Aires, Argentina
| | - Diego Gonzalez
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Departamento de Bioquimica Clinica, Catedra de Bioquimica Clinica I, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Instituto de Fisiopatologia y Bioquimica Clinica (INFIBIOC), Buenos Aires, Argentina
| | - Micaela Lombardo
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Departamento de Bioquimica Clinica, Catedra de Bioquimica Clinica I, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Instituto de Fisiopatologia y Bioquimica Clinica (INFIBIOC), Buenos Aires, Argentina
| | - Alejandro Garcia Escudero
- Hospital General Doctor Cosme Argerich, Division de Cardiologia, Unidad de Hemodinamia, Buenos Aires, Argentina
| | - Gerardo Gigena
- Hospital General Doctor Cosme Argerich, Division de Cardiologia, Unidad de Hemodinamia, Buenos Aires, Argentina
| | - Federico Blanco
- Hospital General Doctor Cosme Argerich, Division de Cardiologia, Unidad de Hemodinamia, Buenos Aires, Argentina
| | - Laura Schreier
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Departamento de Bioquimica Clinica, Catedra de Bioquimica Clinica I, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Instituto de Fisiopatologia y Bioquimica Clinica (INFIBIOC), Buenos Aires, Argentina
| | - Bibiana Fabre
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Departamento de Bioquimica Clinica, Catedra de Bioquimica Clinica I, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Instituto de Fisiopatologia y Bioquimica Clinica (INFIBIOC), Buenos Aires, Argentina
| | - Gabriela Berg
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Departamento de Bioquimica Clinica, Catedra de Bioquimica Clinica I, Buenos Aires, Argentina.,Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Instituto de Fisiopatologia y Bioquimica Clinica (INFIBIOC), Buenos Aires, Argentina.,Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina
| |
Collapse
|
34
|
Lindau R, Mehta RB, Lash GE, Papapavlou G, Boij R, Berg G, Jenmalm MC, Ernerudh J, Svensson-Arvelund J. Interleukin-34 is present at the fetal-maternal interface and induces immunoregulatory macrophages of a decidual phenotype in vitro. Hum Reprod 2019; 33:588-599. [PMID: 29579271 DOI: 10.1093/humrep/dey037] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Accepted: 02/05/2018] [Indexed: 01/22/2023] Open
Abstract
STUDY QUESTION Is the newly discovered cytokine interleukin (IL)-34 expressed at the human fetal-maternal interface in order to influence polarization of monocytes into macrophages of a decidual immunoregulatory phenotype? SUMMARY ANSWER IL-34 was found to be present at the fetal-maternal interface, in both fetal placenta and maternal decidua, and it was able to polarize monocytes into macrophages of a decidual phenotype. WHAT IS KNOWN ALREADY IL-34 was shown to bind to the same receptor as macrophage-colony stimulating factor (M-CSF), which has an important immunomodulatory role at the fetal-maternal interface, for example by polarizing decidual macrophages to an M2-like regulatory phenotype. IL-34 is known to regulate macrophage subsets, such as microglia and Langerhans cells, but its presence at the fetal-maternal interface is unknown. STUDY DESIGN, SIZE, DURATION The presence of IL-34 at the fetal-maternal interface was evaluated by immunohistochemistry (IHC) and ELISA in placental and decidual tissues as well as in isolated trophoblast cells and decidual stromal cells obtained from first trimester elective surgical terminations of pregnancy (n = 49). IL-34 expression was also assessed in third trimester placental biopsies from women with (n = 21) or without (n = 15) pre-eclampsia. The effect of IL-34 on macrophage polarization was evaluated in an in vitro model of blood monocytes obtained from healthy volunteers (n = 14). In this model, granulocyte macrophage-colony stimulating factor (GM-CSF) serves as a growth factor for M1-like polarization, and M-CSF as a growth factor for M2-like polarization. PARTICIPANTS/MATERIALS, SETTING, METHODS First trimester placental and decidual tissues were obtained from elective pregnancy terminations. Placental biopsies were obtained from women with pre-eclampsia and matched controls in the delivery ward. Polarization of macrophages in vitro was determined by flow-cytometric phenotyping and secretion of cytokines and chemokines in cell-free supernatants by multiplex bead assay. MAIN RESULTS AND THE ROLE OF CHANCE Our study shows that IL-34 is produced at the fetal-maternal interface by both placental cyto- and syncytiotrophoblasts and decidual stromal cells. We also show that IL-34, in vitro, is able to polarize blood monocytes into macrophages with a phenotype (CD14highCD163+CD209+) and cytokine secretion pattern similar to that of decidual macrophages. The IL-34-induced phenotype was similar, but not identical to the phenotype induced by M-CSF, and both IL-34- and M-CSF-induced macrophages were significantly different (P < 0.05-0.0001 depending on marker) from GM-CSF-polarized M1-like macrophages. Our findings suggest that IL-34 is involved in the establishment of the tolerant milieu found at the fetal-maternal interface by skewing polarization of macrophages into a regulatory phenotype. LIMITATIONS, REASONS FOR CAUTION Although it is clear that IL-34 is present at the fetal-maternal interface and polarizes macrophages in vitro, its precise role in vivo remains to be established. WIDER IMPLICATIONS OF THE FINDINGS The recently discovered cytokine IL-34 is present at the fetal-maternal interface and has immunomodulatory properties with regard to induction of decidual macrophages, which are important for a healthy pregnancy. Knowledge of growth factors related to macrophage polarization can potentially be translated to treatment of pregnancy complications involving dysregulation of this process. STUDY FUNDING/COMPETING INTEREST(S) This study was funded by grants from the Medical Research Council (Grant K2013-61X-22310-01-04), the Research Council of South-East Sweden (FORSS), and the County Council of Östergötland, Sweden. No author has any conflicts of interest to declare.
Collapse
Affiliation(s)
- R Lindau
- Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden
| | - R B Mehta
- Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden
| | - G E Lash
- Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, CN-510623 Guangzhou, China
| | - G Papapavlou
- Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden
| | - R Boij
- Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden.,Department of Obstetrics and Gynecology, County Hospital Ryhov, SE-551 85 Jönköping, Sweden
| | - G Berg
- Department of Obstetrics and Gynecology, and Department of Clinical and Experimental Medicine, Linköping University, SE-581 83 Linköping, Sweden
| | - M C Jenmalm
- Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden
| | - J Ernerudh
- Department of Clinical Immunology and Transfusion Medicine, and Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden
| | - J Svensson-Arvelund
- Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, SE-581 83 Linköping, Sweden
| |
Collapse
|
35
|
Berg G, Miksztowicz V, Morales C, Barchuk M. Epicardial Adipose Tissue in Cardiovascular Disease. Advances in Experimental Medicine and Biology 2019; 1127:131-143. [DOI: 10.1007/978-3-030-11488-6_9] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
36
|
Barchuk M, Miksztowicz V, Zago V, Cevey A, López G, Goren N, Friedman S, Gelpi RJ, Morales C, Fernandez Tomé MDC, Schreier L, Berg G. Endothelial Lipase Is an Alternative Pathway for Fatty Acid Release from Lipoproteins: Evidence from a High Fat Diet Model of Obesity in Rats. Lipids 2018; 53:993-1003. [DOI: 10.1002/lipd.12107] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Revised: 10/19/2018] [Accepted: 10/26/2018] [Indexed: 11/06/2022]
Affiliation(s)
- Magalí Barchuk
- Departamento de Bioquímica Clínica. Laboratorio de Lípidos y Aterosclerosis, Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
- Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
| | - Verónica Miksztowicz
- Departamento de Bioquímica Clínica. Laboratorio de Lípidos y Aterosclerosis, Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
- Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
- CONICET. Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
| | - Valeria Zago
- Departamento de Bioquímica Clínica. Laboratorio de Lípidos y Aterosclerosis, Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
- Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
- CONICET. Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
| | - Agata Cevey
- CONICET. Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina; Universidad de Buenos Aires, Paraguay 2155 (1121); Buenos Aires Argentina
| | - Graciela López
- Departamento de Bioquímica Clínica. Laboratorio de Lípidos y Aterosclerosis, Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
- Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
| | - Nora Goren
- CONICET. Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS). Facultad de Medicina; Universidad de Buenos Aires, Paraguay 2155 (1121); Buenos Aires Argentina
| | - Silvia Friedman
- Facultad de Odontología. Cátedra de Bioquímica General y Bucal; Universidad de Buenos Aires, Marcelo T. de Alvear 2142 (1122); Buenos Aires Argentina
| | - Ricardo Jorge Gelpi
- Departamento de Patología, Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Universidad de Buenos Aires, Uriburu 950 (1121); Buenos Aires Argentina
| | - Celina Morales
- Departamento de Patología, Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Universidad de Buenos Aires, Uriburu 950 (1121); Buenos Aires Argentina
| | - María del Carmen Fernandez Tomé
- Facultad de Farmacia y Bioquímica. Cátedra de Biología Celular y Molecular. Instituto de Química y Fisicoquímica Biológicas (IQUIFIB). CONICET; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
| | - Laura Schreier
- Departamento de Bioquímica Clínica. Laboratorio de Lípidos y Aterosclerosis, Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
- Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
| | - Gabriela Berg
- Departamento de Bioquímica Clínica. Laboratorio de Lípidos y Aterosclerosis, Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
- Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
- CONICET. Facultad de Farmacia y Bioquímica; Universidad de Buenos Aires, Junin 956 (1113); Buenos Aires Argentina
| |
Collapse
|
37
|
Barchuk M, Schreier L, Berg G, Miksztowicz V. Metalloproteinases in non-alcoholic fatty liver disease and their behavior in liver fibrosis. Horm Mol Biol Clin Investig 2018; 41:/j/hmbci.ahead-of-print/hmbci-2018-0037/hmbci-2018-0037.xml. [PMID: 30171810 DOI: 10.1515/hmbci-2018-0037] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Accepted: 07/10/2018] [Indexed: 01/15/2023]
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a clinical entity of high prevalence in the world characterized by fatty infiltration of liver tissue in the absence of alcohol consumption. The natural history of the disease develops in successive phases reflected in different histological stages, with 10-20% of patients developing liver cirrhosis and fibrosis. Fibrosis is a basic connective tissue lesion defined by the increase of the fibrillary extracellular matrix (ECM) components in a tissue or organ. Matrix metalloproteinases (MMPs) constitute a family of endopeptidases, which are involved in ECM and basement membranes components degradation. Fibrogenic process is characterized by altered ECM composition, associated with modifications in MMPs behavior. The active cross-talk between adipose tissue and liver can be altered in pathologies associated to insulin resistance (IR), such as NAFLD. The role of adipokines on MMPs behavior in the liver could be partly responsible of liver damage during IR. The aim of this revision is to describe the behavior of MMPs in NAFLD and its role in the associated fibrosis.
Collapse
Affiliation(s)
- Magalí Barchuk
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| | - Laura Schreier
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
| | - Gabriela Berg
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
- Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Laboratorio de Lípidos y Aterosclerosis, Junin 956, Buenos Aires, Argentina, Phone: +5411-4964-8297, Fax: +5411-5950-8692
| | - Verónica Miksztowicz
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Bioquímica Clínica I, Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Buenos Aires, Argentina
- Universidad de Buenos Aires, CONICET, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina
| |
Collapse
|
38
|
Mazo T, D´Annunzio V, Zaobornyj T, Perez V, Gomez A, Berg G, Barchuk M, Ossani G, Martinefski M, Tripodi V, Lago N, Gelpi RJ. High-fat diet abolishes the cardioprotective effects of ischemic postconditioning in murine models despite increased thioredoxin-1 levels. Mol Cell Biochem 2018; 452:153-166. [DOI: 10.1007/s11010-018-3421-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Accepted: 08/01/2018] [Indexed: 12/30/2022]
|
39
|
Bruno V, Roepke E, Nedstrand E, Boij R, Pettersson C, Piccione E, Berg G, Svensson-Arvelund J, Jenmalm M, Rubor M, Ernerudh J. Low molecular weight heparin effects on the immune response during pregnancy in women with unexplained recurrent pregnancy loss. J Reprod Immunol 2018. [DOI: 10.1016/j.jri.2018.05.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
40
|
Barchuk M, Miksztowicz V, Lopez G, Rubio M, Schreier L, Berg G. Lipoprotein Lipase Behavior in Epicardial Adipose Tissue of Patients with Coronary Artery Disease. ATHEROSCLEROSIS SUPP 2018. [DOI: 10.1016/j.atherosclerosissup.2018.04.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
41
|
Wallwitz J, Eichinger B, Berg G, Gadermaier E, Himmler G. FP282DEVELOPMENT OF AN IMMUNOASSAY THAT REVEALS ALTERED URINARY VANIN-1 IN HUMAN WITH KIDNEY DISEASE. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.fp282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | | | - Gabriela Berg
- Marketing, Biomedica Medizinprodukte GmbH & Co KG, Vienna, Austria
| | | | | |
Collapse
|
42
|
Wallwitz J, Eichinger B, Berg G, Gadermaier E. SP278VALIDATIONOF A C-TERMINAL FGF23MULTI-MATRIX SANDWICH ELISA FOR THE DETECTION OF FGF23 IN HUMAN SERUM AND PLASMA. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.sp278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | - Gabriela Berg
- Marketing, Biomedica Medizinprodukte GmbH & Co KG, Vienna, Austria
| | | |
Collapse
|
43
|
Suciu AAM, Wallwitz J, Berg G, Himmler G. SP046NEW BIOACTIVE ANGIOPOIETIN-2 ELISA ALLOWS ACCURATE QUANTIFICATION OF ANGIOGENIC FACTOR ANGIOPOIETIN-2 IN KIDNEY DISEASE. Nephrol Dial Transplant 2018. [DOI: 10.1093/ndt/gfy104.sp046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | - Gabriela Berg
- Marketing, Biomedica Medizinprodukte GmbH & Co KG, Vienna, Austria
| | | |
Collapse
|
44
|
Lichtenauer M, Wheatley SD, Martyn-St James M, Duncan MJ, Cobayashi F, Berg G, Musso C, Graffigna M, Soutelo J, Bovet P, Kollias A, Stergiou GS, Grammatikos E, Griffiths C, Ingle L, Jung C. Efficacy of anthropometric measures for identifying cardiovascular disease risk in adolescents: review and meta-analysis. Minerva Pediatr 2018; 70:371-382. [PMID: 29651834 DOI: 10.23736/s0026-4946.18.05175-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
INTRODUCTION To compare the ability of Body Mass Index (BMI), waist circumference (WC) and waist to height ratio (WHtR) to estimate cardiovascular disease (CVD) risk levels in adolescents. EVIDENCE ACQUISITION A systematic review and meta-analysis was performed after a database search for relevant literature (Cochrane, Centre for Review and Dissemination, PubMed, British Nursing Index, CINAHL, BIOSIS citation index, ChildData, metaRegister). EVIDENCE SYNTHESIS The study included 117 records representing 96 studies with 994,595 participants were included in the systematic review, 14 of which (13 studies, N.=14,610) were eligible for the meta-analysis. The results of the meta-analysis showed that BMI was a strong indicator of systolic blood pressure, diastolic blood pressure, triglycerides, high-density lipoprotein cholesterol and insulin; but not total cholesterol, low-density lipoprotein or glucose. Few studies were eligible for inclusion in the meta-analysis considering WC or WHtR (N.≤2). The narrative synthesis found measures of central adiposity to be consistently valid indicators of the same risk factors as BMI. CONCLUSIONS BMI was an indicator of CVD risk. WC and WHtR were efficacious for indicating the same risk factors BMI performed strongly for, though there was insufficient evidence to judge the relative strength of each measure possibly due to heterogeneity in the methods for measuring and classifying WC.
Collapse
Affiliation(s)
- Michael Lichtenauer
- Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Salzburg, Austria
| | - Sean D Wheatley
- School of Sport, Carnegie Faculty, Leeds Beckett University, Leeds, UK -
| | | | - Michael J Duncan
- Faculty of Health and Life Sciences, Coventry University, Coventry, UK
| | - Fernanda Cobayashi
- Public Health Nutrition Program, School of Public Health, University of São Paulo, São Paulo, Brazil
| | - Gabriela Berg
- Lipids and Atherosclerosis Laboratory, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
| | - Carla Musso
- Division of Endocrinology, Milstein Hospital, Buenos Aires, Argentina
| | - Mabel Graffigna
- Division of Endocrinology, Carlos Durand Hospital, Buenos Aires, Argentina
| | - Jimena Soutelo
- Service Endocrinology, Churruca Visca Hospital, Buenos Aires, Argentina
| | - Pascal Bovet
- University Institute of Social and Preventive Medicine, Lausanne, Switzerland and Ministry of Health, Victory, Republic of Seychelles
| | - Anastasios Kollias
- Hypertension Center STRIDE-7, Third Department of Medicine, School of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - George S Stergiou
- Hypertension Center STRIDE-7, Third Department of Medicine, School of Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | | | - Claire Griffiths
- School of Sport, Carnegie Faculty, Leeds Beckett University, Leeds, UK
| | - Lee Ingle
- Department of Sport, Health & Exercise Science, University of Hull, Hull, UK
| | - Christian Jung
- Division of Cardiology, Faculty of Medicine, Pulmonology and Vascular Medicine, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| |
Collapse
|
45
|
Araújo-Moura K, De Moraes ACF, Forkert ECO, Berg G, Cucato GG, Forjaz CLDM, Moliterno P, Gaitan-Charry D, Delgado CA, González-Gil EM, Moreno LA, Carvalho HB, Torres-Leal FL. Is the Measurement of Blood Pressure by Automatic Monitor in the South American Pediatric Population Accurate? SAYCARE Study. Obesity (Silver Spring) 2018; 26 Suppl 1:S41-S46. [PMID: 29464919 DOI: 10.1002/oby.22119] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Revised: 12/20/2017] [Accepted: 12/21/2017] [Indexed: 11/06/2022]
Abstract
OBJECTIVE This study aimed to test the validity of an automatic oscillometric device to measure the blood pressure (BP) in children (n = 191) and adolescents (n = 127) aged 3 to 18 years. METHODS Systolic BP (SBP) and diastolic BP (DBP) levels were measured simultaneous by automatic device and mercury column with Y-connection. To verify the validity, Bland-Altman plots and limits of agreement of 95% (95% LOA), specificity and sensitivity of the device, and the grade of British Hypertension Society (BHS) criteria were used. RESULTS The monitor measurements demonstrated lower measurement bias (mean difference [95% LOA]): 1.4 (-9.9 to 12.8) mmHg in children and 4.3 (-7.8 to 16.5) mmHg in adolescents for SBP. For DBP, it was 2.2 (-7.4 to 11.7) mmHg in children and 1.4 (-8.4 to 11.1) mmHg in adolescents. The sensitivity in children was 21.4 (95% CI = 16.3-26.6), and in adolescents, it was 20.0 (95% CI = 13.2-26.8); the specificity was 95.9 (95% CI = 93.4-98.4) in children and 100.0 (95% CI = 100.0-100.0) in adolescents. The monitor-tested ratings are Grade B for SBP in children and SBP and DBP in adolescents and Grade C for DBP in children. CONCLUSIONS The automatic monitor presented high values of specificity and lower values of sensitivity to the diagnosis of HBP; however, it can be considered accurate (lower measurement bias) and valid for epidemiological and clinical practice in accordance with BHS criteria.
Collapse
Affiliation(s)
- Keisyanne Araújo-Moura
- DOMEN (Metabolic Diseases, Exercise and Nutrition) Research Group, Center for Health Sciences, Federal University of Piaui, Teresina, Brazil
- Youth/Child and Cardiovascular Risk and Environmental Research Group, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Augusto César Ferreira De Moraes
- Youth/Child and Cardiovascular Risk and Environmental Research Group, School of Medicine, University of São Paulo, São Paulo, Brazil
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
| | - Elsie C O Forkert
- Youth/Child and Cardiovascular Risk and Environmental Research Group, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Gabriela Berg
- Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
| | | | | | - Paula Moliterno
- School of Nutrition, University of the Republic, Montevideo, Uruguay
| | - Diego Gaitan-Charry
- School of Nutrition of Dietetics, University of Antioquia, Medellin, Colombia
| | | | - Esther M González-Gil
- Growth, Exercise, Nutrition and Development (GENUD) Research Group, Instituto Agroalimentário de Aragón (IA2), Faculty of Health Sciences, University of Zaragoza, Zaragoza, Spain
| | - Luis Alberto Moreno
- Growth, Exercise, Nutrition and Development (GENUD) Research Group, Instituto Agroalimentário de Aragón (IA2), Faculty of Health Sciences, University of Zaragoza, Zaragoza, Spain
| | - Heráclito Barbosa Carvalho
- Youth/Child and Cardiovascular Risk and Environmental Research Group, School of Medicine, University of São Paulo, São Paulo, Brazil
| | - Francisco Leonardo Torres-Leal
- DOMEN (Metabolic Diseases, Exercise and Nutrition) Research Group, Center for Health Sciences, Federal University of Piaui, Teresina, Brazil
| |
Collapse
|
46
|
Carvalho HB, Moreno LA, Silva AM, Berg G, Estrada-Restrepo A, González-Zapata LI, De Miguel-Etayo P, Delgado CA, Bove MI, de Sousa MDLR, Torres-Leal FL, Forjaz CLM, De Moraes ACF. Design and Objectives of the South American Youth/Child Cardiovascular and Environmental (SAYCARE) Study. Obesity (Silver Spring) 2018; 26 Suppl 1:S5-S13. [PMID: 29464921 DOI: 10.1002/oby.22117] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Revised: 11/29/2017] [Accepted: 12/14/2017] [Indexed: 11/07/2022]
Abstract
OBJECTIVE The purpose of this paper is to introduce the overarching study design of the South American Youth/Child Cardiovascular and Environmental (SAYCARE) study, which is an observational multicenter feasibility study held in seven South American cities: Buenos Aires (Argentina), Lima (Peru), Medellin (Colombia), Montevideo (Uruguay), Santiago (Chile), and São Paulo and Teresina (Brazil). Children and adolescents (3-17 years of age) were studied. METHODS The data management systems, quality assurance monitoring activities, standardized operating procedure manuals, and training and study management are addressed in this paper. Various quality controls to ensure the collection of valid and reliable data are also discussed. RESULTS AND CONCLUSIONS Data were obtained from 237 preschoolers and schoolchildren and 258 adolescents during the validation phase measurements. The results of the SAYCARE study are expected to provide higher accuracy in the assessment of cardiovascular disease risk factors, including eating behaviors, body composition, physical activity, sedentary behaviors, lipid profiles and cardiovascular health biomarkers, oral health, social conditions, environmental factors and home environment, and their determinants in children and adolescents from ages 3 to 17 in seven South American cities.
Collapse
Affiliation(s)
- Heráclito Barbosa Carvalho
- Youth/Child Cardiovascular Risk and Environmental Research Group, Department of Preventive Medicine, School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil
| | - Luis Alberto Moreno
- Growth, Exercise, Nutrition and Development Research Group, Faculty of Health Sciences, University of Zaragoza, Zaragoza, Spain
- Agroalimentary Institute of Aragon, University of Zaragoza, Zaragoza, Spain
- Biomedical Research Networking Center-Physiopathology of Obesity and Nutrition (CIBERObn), University of Zaragoza, Zaragoza, Spain
| | - Andrew Mello Silva
- Youth/Child Cardiovascular Risk and Environmental Research Group, Department of Preventive Medicine, School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil
- Technical College of São Paulo, São Paulo, São Paulo, Brazil
| | - Gabriela Berg
- School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
| | - Alejandro Estrada-Restrepo
- Demography and Health Research Group, School of Nutrition and Dietetics, University of Antioquia, Medellin, Colombia
| | - Laura Inés González-Zapata
- Social and Economic Determinants of Health and Nutrition Research Group, School of Nutrition and Dietetics, University of Antioquia, Medellin, Colombia
| | - Pilar De Miguel-Etayo
- Growth, Exercise, Nutrition and Development Research Group, Faculty of Health Sciences, University of Zaragoza, Zaragoza, Spain
- Agroalimentary Institute of Aragon, University of Zaragoza, Zaragoza, Spain
- Biomedical Research Networking Center-Physiopathology of Obesity and Nutrition (CIBERObn), University of Zaragoza, Zaragoza, Spain
| | - Carlos Alberto Delgado
- Department of Pediatrics, School of Medicine, National University of San Marcos, Lima, Peru
- Neonatal Unit, National Institute of Child Health, Lima, Peru
| | - María Isabel Bove
- Health and Welfare Institute, School of Psychology, Catholic University of Uruguay, Montevideo, Uruguay
| | | | - Francisco Leonardo Torres-Leal
- Metabolic Diseases, Exercise and Nutrition Research Group, Center for Health Sciences, Federal University of Piaui, Teresina, Brazil
| | - Claudia L M Forjaz
- Exercise Hemodynamic Laboratory, School of Physical Education and Sport, University of São Paulo, São Paulo, São Paulo, Brazil
| | - Augusto César Ferreira De Moraes
- Youth/Child Cardiovascular Risk and Environmental Research Group, Department of Preventive Medicine, School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
| | | |
Collapse
|
47
|
Weisstaub AR, Salinas MV, Correa MJ, Barchuk M, Berg G, Zuleta A. Effects of the intake of white wheat bread added with garlic and resistant starch: action on calcium bioavailability and metabolic parameters of growing Wistar rats. Food Funct 2018; 9:5707-5714. [DOI: 10.1039/c8fo01407h] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Functional bread with resistant starch and garlic improved the metabolism of calcium and lipids and the growth of beneficial gut microbiota.
Collapse
Affiliation(s)
- Adriana R. Weisstaub
- Departamento de Nutrición y Bromatología
- Facultad de Farmacia y Bioquímica
- Universidad de Buenos Aires
- Buenos Aires
- Argentina
| | - María Victoria Salinas
- Centro de Investigación y Desarrollo en Criotecnología de Alimentos (CIDCA) (Facultad de Ciencias Exactas-UNLP
- CIC
- CONICET)
- La Plata
- Argentina
| | - María Jimena Correa
- Centro de Investigación y Desarrollo en Criotecnología de Alimentos (CIDCA) (Facultad de Ciencias Exactas-UNLP
- CIC
- CONICET)
- La Plata
- Argentina
| | - Magalí Barchuk
- Laboratorio de Lipidos y Aterosclerosis
- Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC)
- Departamento de Bioquímica Clínica
- Facultad de Farmacia y Bioquímica
- Universidad de Buenos Aires
| | - Gabriela Berg
- Laboratorio de Lipidos y Aterosclerosis
- Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC)
- Departamento de Bioquímica Clínica
- Facultad de Farmacia y Bioquímica
- Universidad de Buenos Aires
| | - Angela Zuleta
- Departamento de Nutrición y Bromatología
- Facultad de Farmacia y Bioquímica
- Universidad de Buenos Aires
- Buenos Aires
- Argentina
| |
Collapse
|
48
|
Miksztowicz V, Morales C, Barchuk M, López G, Póveda R, Gelpi R, Schreier L, Rubio M, Berg G. Metalloproteinase 2 and 9 Activity Increase in Epicardial Adipose Tissue of Patients with Coronary Artery Disease. Curr Vasc Pharmacol 2017; 15:135-143. [PMID: 27781958 DOI: 10.2174/1570161114666161024124244] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2016] [Revised: 10/02/2016] [Accepted: 10/04/2016] [Indexed: 11/22/2022]
Abstract
BACKGROUND Epicardial adipose tissue (EAT) is a visceral adipose tissue (AT) surrounding and infiltrating myocardium and coronary arteries. Increased EAT may represent a chronic inflammatory injury and a link with coronary artery disease (CAD). Metalloproteinases (MMPs) are involved in expansion of AT. OBJECTIVE To evaluate MMP-2 and -9 behaviour in EAT from CAD patients. METHODS In EAT and subcutaneous AT (SAT) from patients undergoing coronary artery bypass graft (CABG, n=26) or valve replacement (No CABG, n=18), MMP-2 and -9 activity and localization, inflammatory cells and vascular endothelial growth factor (VEGF) levels were determined. RESULTS In EAT from CABG, MMP-2 and -9 activity was increased compared with No CABG (p=0.041 and p=0.027, respectively) and compared with SAT (p=0.005 and p=0.048, respectively). In CABG patients EAT showed higher infiltration of macrophages and T lymphocytes than SAT (p=0.01 and p=0.002, respectively). In No CABG patients no sign of cellular retention was observed in EAT or SAT. Vascular density was higher in EAT from CABG than No CABG (p=0.015) and it was directly correlated with MMP-2 (p=0.006) and MMP-9 (p=0.02). VEGF levels in EAT were directly associated with MMP-2 (p=0.016). CONCLUSION In EAT from CABG patients the increase of MMP-2 and -9 activity and the presence of inflammatory cells would be partially responsible for extracellular matrix (ECM) remodeling and major vascular density necessary for EAT expansion. Improved knowledge of EAT behaviour may allow to identify new therapeutic targets for the treatment of CAD.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Gabriela Berg
- Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica. Laboratorio de Lípidos y Aterosclerosis, Buenos Aires, Argentina, Junín 956, CABA, Argentina
| |
Collapse
|
49
|
Lucero D, Miksztowicz V, Gualano G, Longo C, Landeira G, Álvarez E, Zago V, Brites F, Berg G, Fassio E, Schreier L. Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins. Clin Chim Acta 2017; 473:1-8. [PMID: 28802640 DOI: 10.1016/j.cca.2017.08.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Revised: 08/07/2017] [Accepted: 08/08/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND We evaluated possible changes in VLDLcharacteristics, and metabolic related factors, in MetS-associated NAFLD and accompanying liver fibrosis. METHODS We studied 36 MetS patients with biopsy-proven NAFLD (MetS+NAFLD) and 24 MetS without ultrasound NAFLD evidence. Further, MetS+NAFLD was sub-divided according to fibrosis stage into, non-to-moderate (F0-F2, n=27) and severe (F3-F4, n=9) fibrosis. We measured: lipid profile, VLDL composition and size (size exclusion-HPLC), CETP and lipoprotein lipase (LPL) activities and adiponectin. Additionally, in MetS+NAFLD type IV collagen 7S domain was measured. RESULTS MetS+NAFLD showed increased VLDL-mass, VLDL particle number, VLDL-triglyceride% and large VLDL-% (p<0.04). CETP activity tended to increase in MetS+NAFLD (p=0.058), while LPL activity was unchanged. Moreover, in MetS+NAFLD, adiponectin was decreased (p<0.001), and negatively correlated with VLDL-mass and VLDL particle number (p<0.05), independently of insulin-resistance. Within MetS+NAFLD group, despite greater insulin-resistance, patients with severe fibrosis showed lower plasma triglycerides, VLDL-mass, VLDL-triglyceride%, large VLDL-% and CETP activity (p<0.05), while type IV collagen was increased (p=0.009) and inversely correlated with large VLDL-% (p=0.045). CONCLUSIONS In MetS, NAFLD is associated with larger and triglyceride over-enriched circulating VLDLs, of greater atherogenicity. However, when NAFLD progresses to severe fibrosis, circulating VLDL features apparently improved, probably due to early alterations in hepatic synthetic function.
Collapse
Affiliation(s)
- Diego Lucero
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Argentina; Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.
| | - Verónica Miksztowicz
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Argentina; Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Gisela Gualano
- Liver Unit, Department of Medicine, Hospital Nacional "Profesor Alejandro Posadas", El Palomar, Buenos Aires, Argentina
| | - Cristina Longo
- Liver Unit, Department of Medicine, Hospital Nacional "Profesor Alejandro Posadas", El Palomar, Buenos Aires, Argentina
| | - Graciela Landeira
- Liver Unit, Department of Medicine, Hospital Nacional "Profesor Alejandro Posadas", El Palomar, Buenos Aires, Argentina
| | - Estela Álvarez
- Pathology Service, Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, Argentina
| | - Valeria Zago
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Argentina; Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Fernando Brites
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Argentina; Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Gabriela Berg
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Argentina; Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
| | - Eduardo Fassio
- Liver Unit, Department of Medicine, Hospital Nacional "Profesor Alejandro Posadas", El Palomar, Buenos Aires, Argentina
| | - Laura Schreier
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Argentina; Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Argentina
| |
Collapse
|
50
|
Corral P, Geller A, Polisecki E, Bañares V, López G, Berg G, Cacciagiú L, Hegele R, Schaefer E, Schreier L. Genetic studies in definite/probable FH in Argentina. Atherosclerosis 2017. [DOI: 10.1016/j.atherosclerosis.2017.06.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|